US Clinical Development and Medical Affairs 
AIN457/Secukinumab 
Clinical
 Trial Protocol CAIN457FUS06 / [STUDY_ID_REMOVED]
A randomized, double -blind, parallel-g roup, multicenter 
study of secukinumab to compare 300 mg and 150 mg at 
Week 52 in patients with Ankylosing Spondylitis who are 
randomized to dose escalation after not achieving inactive 
disease during an initial 16 week s of open -label treatment 
with secukinumab 150 mg (ASLeap)  
Document type:  Amended Protocol Version  
EUDRACT number:  Not Applicable  
Version number:  v04 (Track Changes ) 
Clinical trial phase:  IV 
Release date:  20-Aug-2020
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 3.4 (May 2017)  
[COMPANY_001]  Confidential  Page 2 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Table of contents  
Table of contents ................................................................................................................. [ADDRESS_99357] of abbreviations  ............................................................................................................ 6 
Glossary of Terms  ............................................................................................................... 8 
Protocol Summary  ............................................................................................................... 9 
1 Introduction ....................................................................................................................... 18 
1.1 Background ............................................................................................................ 18 
1.2 Rationale for protocol amendment  ........................ Error! Bookmark not defined.  
1.3 Changes to protocol  ............................................... Error! Bookmark not defined.  
1.4 Purpose .................................................................................................................. 20 
2 Study objective and endpoints ........................................................................................... 20 
2.1 Objectives and related endpoints ........................................................................... 20 
3 Investigational Plan  ........................................................................................................... 24 
3.1 Study design .......................................................................................................... 24 
3.2 Rationale for study design ..................................................................................... 25 
3.3 Rationale for dose/regimen, route of administration and duration of treatment .... 26 
3.4 Rationale for choice of comparator  ....................................................................... 27 
3.5 Purpose and timing of interim analyses/design adaptations .................................. 27 
3.6 Risks and benefits .................................................................................................. 27 
4 Population .......................................................................................................................... 28 
4.1 Inclusion Criteria  ................................................................................................... 28 
4.2 Exclusion Criteria  .................................................................................................. 29 
5 Treatment  ........................................................................................................................... 32 
5.1 Study treatment ...................................................................................................... 32 
5.1.1  Investigational and control drugs .......................................................... 32 
5.1.2  Additional treatment .............................................................................. 32 
5.2 Treatment arms  ...................................................................................................... 32 
5.3 Treatment assignment and randomization  ............................................................. 34 
5.4 Treatment Blinding  ................................................................................................ 34 
5.5 Treating the patient  ................................................................................................ 35 
5.5.1  Patient numbering  ................................................................................. 35 
5.5.2  Dispensing the study drug ..................................................................... 35 
5.5.3  Handling of study and additional treatment .......................................... 35 
5.5.4  Instructions for prescribing and taking study treatment ........................ 36 
[COMPANY_001]  Confidential  Page 3 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
5.5.[ADDRESS_99358]- study treatment  .......................................... 41 
5.6.2  Discontinuation of study treatment  ....................................................... 41 
5.6.3  Withdrawal of informed consent  ........................................................... 42 
5.6.4  Loss to follow-up .................................................................................. 42 
5.6.5  Early study termination by [CONTACT_456] ................................................. 43 
6 Visit schedule and assessments  ......................................................................................... 43 
6.1 Rescreening ............................................................................................................ 50 
6.2 Information to be collected on screening failures .................................................. 50 
6.3 Patient demographics/other baseline characteristics ............................................. 50 
6.4 Treatment exposure and compliance ..................................................................... 51 
6.5 Efficacy  .................................................................................................................. 51 
6.5.1  ASDAS and ASDAS response categories  ............................................. 51 
6.5.2  Assessment of Spondylo -Arthritis International Society criteria 
(ASAS)  .................................................................................................. 52 
  54 
6.5.4  ASAS Health Index (ASAS -HI) ........................................................... 54 
  54 
6.5.6  Functional Assessment of Chronic Illness Therapy – Fatigue 
(FACIT -Fatigue) ................................................................................... [ADDRESS_99359] x -ray ............................................................................................ 56 
6.6.3  Electrocardiogram (ECG) ..................................................................... 56 
6.6.4  Physical examination  ............................................................................ 57 
6.6.5  Vital signs .............................................................................................. 57 
6.6.6  Height and weight  ................................................................................. 57 
6.6.7  Laboratory evaluations  .......................................................................... 57 
6.6.8  Pregnancy and assessments of fertility  ................................................. 58 
6.6.9  Documented radiologic evidence fulfilling t he NY criteria for AS  ...... 58 
6.6.10  Tolerability of secukinumab  ................................................................. 58 

[COMPANY_001]  Confidential  Page 4 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
6.6.11  Local tolerability  ................................................................................... 58 
6.6.12  Appropriateness of safety measures  ...................................................... 59 
  59 
  59 
  60 
  60 
7 Safety Monitoring  .............................................................................................................. 61 
7.1 Adverse events ....................................................................................................... 61 
7.2 Serious Adverse Events  ......................................................................................... 62 
7.2.1  Definition of SAE  ................................................................................. 62 
7.3 Liver safety monitoring  ......................................................................................... 64 
7.4 Renal safety monitoring  ......................................................................................... 64 
7.5 Reporting of study treatment errors including misuse/abuse ................................ 64 
7.6 Pregnancy Reporting  ............................................................................................. 65 
8 Data review and database management  ............................................................................. 65 
8.1 Site monitoring  ...................................................................................................... 65 
8.2 Data collection  ....................................................................................................... 66 
8.3 Database management and quality control ............................................................ 66 
8.4 Data monitoring committee  ................................................................................... 67 
8.5 Adjudication committee ......................................................................................... 67 
9 Data analysis ...................................................................................................................... 67 
9.1 Analysis sets .......................................................................................................... 67 
9.2 Patient demographics and other baseline characteristics  ....................................... 68 
9.3 Treatments  ............................................................................................................. 68 
9.4 Analysis of the primary variable(s)  ....................................................................... 68 
9.4.1  Primary variable(s)  ................................................................................ 68 
9.4.2  Statistical model, hypothesis, and method of analysis .......................... 68 
9.4.3  Handling of missing values/censoring/discontinuations  ....................... 68 
9.4.4  Sensitivity analyses  ............................................................................... 69 
9.5 Analysis of secondary variables  ............................................................................ 69 
9.5.1  Efficacy variables  .................................................................................. 69 
9.5.2  Safety variables  ..................................................................................... 69 
  70 
9.7 Interim analyses  ..................................................................................................... 71 
9.8 Sample size calculation .......................................................................................... 71 
10 Ethical considerations  ........................................................................................................ 71 

[COMPANY_001]  Confidential  Page 5 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
10.1  Regulatory and ethical compliance ........................................................................ 71 
10.2  Informed consent process ...................................................................................... 72 
10.3  Responsibilities of the investigator and IRB/IEC  .................................................. 72 
10.4  Publication of study protocol and results............................................................... 72 
10.5  Quality control and quality assurance.................................................................... 73 
11 Protocol adherence  ............................................................................................................ 73 
11.1  Protocol amendment s............................................................................................. 73 
12 References  ......................................................................................................................... 74 
13 Appendices ........................................................................................................................ 77 
  77 
  78 
13.3  Appendix 3: Assessment of SpondyloArthritis In ternational Society criteria 
(ASAS)  .................................................................................................................. 79 
  79 
13.3.2  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ........ 79 
13.3.3  Appendix 4: Guidelines for administering the PRO questionnaires ..... [ADDRESS_99360] of figures  
Figure 3-1  Study design .......................................................................................... 25 
 

[COMPANY_001]  Confidential  Page 6 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
List of abbreviations  
 
AE Adverse event  
ALT/SGPT  Alanine aminotransferase/serum glutamic pyruvic transaminase  
AS Ankylosing Spondylitis  
ASAS  Ankylosing SpondyloArthritis International Society  
ASAS -HI ASAS Health Index  
ASDAS  Ankylosing Spondylitis Disease Activity Score  
ASQoL  Ankylosing Spondylitis Quality of Life  
AST/SGOT  Aspartate aminotransferase/serum glutamic oxaloacetic transaminase  
BASDAI  Bath Ankylosing Spondylitis Disease Activity index  
  
BMI Body mass index  
BSL Baseline  
COPD  Chronic obstructive pulmonary disorder  
CRF Case Report/Record Form (paper or electronic)  
CRO  Contract  research organization  
CRP  C-reactive protein  
CSR  Clinical study report  
CTC Common Toxicity Criteria  
DMARD  Disease Modifying Anti -rheumatic Drug  
DS&E Drug Safety & Epi[INVESTIGATOR_90147]/Record Form  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
EMA/EMEA  European Medicines (Evaluation) Agency  
FACIT -Fatigue©  Functional Assessment of Chronic Illness Therapy – Fatigue  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
hCG Human chorionic gonadotropin  
HIV Human immunodeficiency virus  
  
IB Investigator’s brochure  
IBD Inflammatory Bowel Disease  
ICF Informed consent form  
IEC Independent Ethics Committee  
ICH International Council on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IFU Instructions for use  
IL Interleukin  
IRB Institutional Review Board  
IRT Interactive Response Technology  

[COMPANY_001]  Confidential  Page 7 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
IUD Intra Uterine Device  
IUS Intra Uterine System  
i.v. intravenous(ly)  
LFT Liver function test  
LLN Lower limit of normal  
  
MedDRA  Medical dictionary for regulatory activities  
MRI Magnetic resonance imaging/image  
mmHg  Millimeter mercury  
MTX  Methotrexate  
NRS  Numeric rating scale  
NSAID  Non-steroidal anti -inflammatory drug  
PBO  Placebo  
PFS Prefilled syringe  
[COMPANY_003] Purified protein derivative  
PRN  Pro re nata  (as required)  
PRO  Patient Reported Outcome  
PsA Psoriatic arthritis  
QoL Quality of Life  
RA Rheumatoid arthritis  
RBC  Red blood cell  
SAE Serious adverse event  
s.c. Subcutaneous(ly)  
SCR  Screening  
SD Standard deviation  
SE Sleep efficiency  
SI Sacroiliac  
SpA Spondyloarthritis  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reactions  
SV1 Screening Visit [ADDRESS_99361] Upper limit of normal  
VAS Visual analog scale  
  
WBC  White blood cell  
WHO  World Health Organization  

[COMPANY_001]  Confidential  Page 8 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Glossary of Terms  
 
Assessment  A procedure used to generate data required by [CONTACT_90166]  A group of newly enrolled patients treated at a specific dose and 
regimen (i.e. treatment group) at the same time  
Control drug  Any drug (an active drug or an inactive drug, such as a placebo) 
which is used as a comparator to the drug being tested in the 
trial 
Dose level  The dose of drug given to the patient (total daily or weekly etc.)  
Enrollment  Point/time of patient entry into the study at  which informed 
consent must be obtained (i.e. prior to starting any of the 
procedures described in the protocol)  
Investigational drug  The drug whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is 
synonymous with “investigational new drug” or “investigational 
medicinal product.”  
Investigational treatment  All investigational drug(s) whose properties are being tested in 
the study as well as their associated treatment controls.  
This includes  any placebos, any active controls, as well as 
approved drugs used outside of their indication/approved dosage or tested in a fixed combination.  
Investigational treatment generally does not include protocol -
specified concomitant background therapi[INVESTIGATOR_90148]  A unique identifier on the label of each investigational/study drug package in studies that dispense medication using an IRT 
system  
Protocol  A written account of all the procedures to be followed in a trial, 
which describes all the administrative, documentation, analytical 
and clinical processes used in the trial.  
Premature subject withdrawal  Point/time when the patient exits from the study prior to the planned completion of all study treatment administration and/or assessments; at this time all study treatment administration is 
discontinued and no further assessments are planned, unless 
the patient will be followed for progression and/or survival  
Randomization number  A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment  
Study drug/ treatment  Any single drug or combination of drugs administered to the 
patient as part of the required study procedures; includes investigational drug (s), active drug run- ins or background 
therapy  
Study/investigational 
treatment discontinuation  Point/time when patient permanently stops taking 
study/investigational treatment  for any reason; may or may not 
also be the point/time of premature patient withdrawal  
Subject Number  A number assigned to each patient who enrolls into the study  
Variable  A measured value or assessed response that is determined in 
specific assessments and used in data analysis to evaluate the 
drug being tested in the study  
[COMPANY_001]  Confidential  Page 9 
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Amendment 04  
Amendment rationale  
This protocol has been modified to add telemedicine/telephone study visits with direct to patient 
shipment of study drug as options available to participants unable to travel to the clinic for a study visit as the result of the COVID19 pandemic. Given the study design, which already allows flexible (home nursing) visits, the addition of telemedicine/telephone study visits with direct to patient shipment of study drug is believed to pose minimal risk to patient safety and data integrity.   
The definition of withdrawal of consent was also updated.    
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions. 
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes herein affect the Informed Consent.  Sites are required to update and submit for approval a revise d Informed Consent that takes into account the changes described in this 
protocol amendment.  
Summary of previous amendments  
Amendment 3 (15- Oct-2018) 
The protocol has been modified to require a patient’s documented radiologic evidence to be 
read by a cen tral reader at Screening Visit 2, correct the total minimum number of weeks during 
the screening period in Figure [ADDRESS_99362] of parameters used for the ASDAS calculation in section 6.5.1, add a section reference to Table 6 -1 Assessment schedule and make grammatical corrections.  
Amendment 2 (07- Feb-2018)  
The protocol has been modified to correct the definition of an Inadequate Responder, revise the screening period assessments related to the delivery of the wearable sensor, reconcile visit assessment inconsistencies, remove duplicate text and revise concomitant medication requirements.  Additionally, copy/paste errors have been removed and protocol clarifications have been made at certain points.  
Amendment 1 (14- Dec-2017)  
The protocol has been modified to change from the  use of visual analog scales (VAS) to numeric 
rating scales (NRS) for the following patient reported outcomes measures: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),  

[COMPANY_001]  Confidential  Page 10  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
 A
dditionally, reconciliation of minor inconsistences and protocol 
clarifications have been made at certain points.   

[COMPANY_001]  Confidential  Page 11  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Protocol Summary 
 
Protocol number  CAIN457FUS06  
Full Title  A randomized, double -blind, parallel -group, multicenter study of 
secukinumab to compare 300 mg and 150 mg at Week 52 in patients with 
Ankylosing Spondylitis who are randomized to dose escalation after not 
achieving inactive disease during an initial 16 weeks of open- label 
treatment with secukinumab 150 mg (ASLeap)   
Brief title  
 Study estimating the clinical difference between [ADDRESS_99363]  of 
increased dose on subsequent clinical outcomes, for which this study aims 
to assess.  
Primary Objective(s)  To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg treatment groups at Week 52 based on the 
proportion of subjects achieving ASDAS inactive disease (< 1.3) status who did not meet ASDAS inactive disease criteria at Week 12 and Week 
16. 
Secondary Objectives  • To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg blinded treatment groups at  Week 52 based 
on the proportion of subjects achieving a ASDAS clinically important improvement from their Week 16 ASDAS score (reduction in ASDAS  ≥  1.1 from Week 16)  
• To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg blinded treatment groups at Week 52 based 
on the change from Week 16 in the total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
• To estimate the difference between secukinumab 300 mg and secukinumab 150 mg blinded treatment groups at Week 52 based 
on the  proportion of subjects achieving BASDAI50 response  
[COMPANY_001]  Confidential  Page 12  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
• To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg blinded treatment groups at Week 52 based 
on the proportion of subjects achieving an Assessment of 
Spondyloarthritis International Society criteria 20 response (ASAS20)  
• To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg blinded treatment groups at Week 52 based 
on the proportion of subjects achieving ASAS40 response  
• To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg blinded treatment groups at Week 52 based 
on the proportion of subjects achieving ASAS partial remission (a value not above 2 units in each of the four main domains on a scale 
of 10)   
• To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg blinded treatment groups at Week 52 based on change from Week 16 in the total score of ASAS Health Index 
(ASAS- HI)   
• To estimate the difference between secukinumab 300 mg and 
secukinumab 150 mg blinded treatment groups at Week 52 based 
on change from Week 16 in the total score of FACIT -Fatigue  
• The overall safety and tolerability of secukinumab  
Study design This study design includes an initial 16 week open- label period (Treatment 
Period 1) followed by a randomized, double- blind, parallel -group period 
(Treatment Period 2).   
During the initial [ADDRESS_99364] met the definition of ASDAS inactive disease, patients will be placed into one of the following three 
groups for the remaining 36 weeks of the trial.  
• Responders: Patients that achieve ASDAS inactive disease (total 
score <  1.3) at both Week 12 and Week 16 and who do achieve a 
decrease (improvement) from baseline in total ASDAS score at both Week 12 and Week 16.  Patients will enter Treatment Period 
2 and continue receiving secukinumab 150 mg through Week 48.  
• Inadequate Responders: Patients who have active disease, 
defined as an ASDAS total score of ≥ 1.3 at either Week 12 or 
Week 16, and  do achieve a decrease (improvement) from baseline 
in total ASDAS score at both Week 12 and Week 16.  Patients will 
enter Treatment Period 2 and be randomized (1:1, double- blinded) 
to secukinumab 300 mg or secukinumab 150 mg through Week 
48. 
• Non-responders : Patients who exhibit no change or an increase 
(worsening) from baseline in total ASDAS score at either Week [ADDRESS_99365] of male and female patients, ≥ 18 years  
of age with a clinical diagnosis of moderate to severe AS fulfilling the 
Modified [LOCATION_001] criteria for AS and with moderate to severe disease 
[COMPANY_001]  Confidential  Page 13  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
despi[INVESTIGATOR_90149] / non -biologic DMARDs and/or anti -
TNFα therapy.  
Patients must have a history of active AS, as measured by [CONTACT_90167]:  
• Total BASDAI of ≥ 4 on a numeric rating scale (NRS) of 0-10 at 
baseline  
• Spi[INVESTIGATOR_90150] #2 of ≥ 4 on a NRS 
of 0-10 at baseline  
• Total back pain of ≥ 4 on a NRS of 0-10 at baseline  
The study aims to enroll approximately 270 patients at approximately 82 
centers in the [LOCATION_002].  Since a 25% screen failure rate is expected, 
approximately 360 patients will be screened.  
Key Inclusion criteria  Patients/subjects eligible for inclusion in this study must fulfill all of  the 
following criteria:  
1. Patient must be able to understand and communicate with the 
investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study 
assessment is performed  
2. Male or non -pregnant, non- lactating female patients at least 18 years 
of age  
3. Diagnosis of moderate to severe AS with prior documented radiologic 
evidence (x -ray or radiologist’s report) fulfilling the Modified [LOCATION_001] 
criteria for AS   
4. Active AS assessed by [CONTACT_90168] ≥ 4 (NRS of 0-10) at baseline  
5. Spi[INVESTIGATOR_90150] #2 of ≥ 4 ( NRS of 0-
10) at bas eline  
6. Total back pain of ≥ 4 (NRS of 0-10) at baseline  
7. Patients should have been on NSAIDs at the maximum tolerated 
dose for at least 4 weeks prior to their Baseline Visit, with an 
inadequate response or for less than 4 weeks if withdrawn for 
intolerance, toxicity or contraindications  
8. Patients who are regularly taking NSAIDs (including COX -1 or COX -
2 inhibitors) as part of their AS therapy are required to be on a stable dose for at least [ADDRESS_99366] been on a TNFα i nhibitor (not more than one) must 
have experienced an inadequate response to previous or current 
treatment given at an approved dose for at least 3 months prior to 
baseline or had been intolerant upon administration of that anti -TNFα 
agent  
Key Exclusion criteria  Patients/subjects fulfilling any of the following criteria during the Screening 
Period or at the Baseline Visit are not eligible for inclusion in this study. No 
additional exclusions may be applied by [CONTACT_093], in order to ensure  
that the study population will be representative of all eligible 
patients/subjects.  
1. Patients with total ankylosis of the spi[INVESTIGATOR_90151] 14  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
2. Use of other investigational drugs within [ADDRESS_99367] magnetic resonance imaging (MRI) with 
evidence of ongoing infectious or malignant process, obtained wit hin 3 
months prior to screening and evaluated by a qualified physician.  
5. Previous exposure to secukinumab or any other biologic drug directly 
targeting IL- 17, IL -12/23, or the IL- [ADDRESS_99368] taken more than one anti -TNFα agent  
7. Any intramuscular or intravenous corticosteroid injection within 2 
weeks before baseline  
8. Any therapy by [CONTACT_90169]- articular injections (e.g. corticosteroid) within [ADDRESS_99369] 5 years 
(except for basal cell carcinoma or actinic keratoses that have been 
treated with no evidence of recurrence in the past [ADDRESS_99370] been removed)  
Study treatment  All patients will receive active secukinumab.  During the first 16 weeks of the trial, all patients will receive 150 mg 
secukinumab.  During the 
remaining 36 weeks of the trial, patients will receive either 150 mg or 300 
mg secukinumab.  
Efficacy assessments  • Ankylosing Spondylitis Disease Activity Score (ASDAS) and ASDAS response categories  
• Assessment of Spondyloarthritis International Society criteria (ASAS)  
•   
•   
•  
• Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
•  
• ASAS- Health Index (ASAS -HI) 
  
 
• FACIT - Fatigue  
Key safety 
assessments • AEs and SAEs including injection site reactions  
• ECGs  
• Physical examination  

[COMPANY_001]  Confidential  Page 15  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
• Vital signs  
• Laboratory assessments  
• Assessment of anti -secukinumab antibody development 
(immunogenicity)  
Other assessments  •  
 
•  
 
 
 
Data analysis The analysis will be conducted on all patient data at the time the trial ends.  
Efficacy, safety, and other data from Treatment Period 1, randomized 
double- blind Treatment Period 2 for inadequate responders, and blinded 
Treatment Period 2 for responders will be summarized.  For continuous 
variables, summary statistics (mean, standard deviation, median, 25th and 
75th percentiles, interquartile range, minimum, and maximum) at each time 
point and for change from baseline to Week 16, and change from Week 16 
to each time point by [CONTACT_5260].  For discrete 
variables, frequency counts and percentages at each time point will be reported by [CONTACT_1570].  
The following analysis sets will be used for the statistical reporting and analyses:  
Enrolled Set:  The Enrolled Set consists of all enrolled patients for the initial 
16-week, Treatment Period 1.  
Responder Set: The Responder Set consists of all patients who are labeled 
as responders at the end of Treatment Period 1, and enter Treatment 
Period 2 receiving blinded secukinumab 150 mg every 4 weeks through Week 48.  
Randomized Set: The Randomized Set consists of all randomized patients.   
Safety Set: The Safety Set includes all patients who received at least one 
dose of study treatment during Treatment Period 2.  Patients will be 
analyzed according to the study treatment received.  
Full Analysis Set:  The Full Analysis Set comprises all patients to whom 
study treatment has been assigned by [CONTACT_17628].  Patients 
inappropriately randomized (e.g., IRT was called in error for randomization 
of a screen failed patient) will be excluded from this analysis set.  According 
to the intent -to-treat principle, patients will be analyzed according to the 
treatment they have been assigned to during the randomization procedure.  
The primary efficacy variable is the ASDAS inactive disease response 
(yes, no).  The primary analysis time point is at Week 52.  
The primary efficacy variable will be analyzed at each time point using a logistic regression model with treatment, TNF -alpha inhibitor status (naive, 
inadequate responder), and baseline body weight as explanatory variables 
(Stokes, Davis , and Koch, 2012
).  The odds ratios and 95% confidence 
intervals for the odds ratios will be reported, based on the fitted model.  

[COMPANY_001]  Confidential  Page 16  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Post-randomization patients who discontinue prematurely for any reason 
will be considered non -responders from the time they discontinued.  In an 
additional analysis, missing data for ASDAS inactive disease response will 
be imputed using multiple imputation.  
The secondary efficacy variables are the following:  
1. Reduction in ASDAS ≥  1.1 from Week 16 (yes, no)  
2. Change from Week 16 in total BAS DAI 
3. BASDAI50 response (yes, no)  
4. ASAS20 response (yes, no)  
5. ASAS40 response (yes, no)  
6. ASAS partial remission (yes, no)  
7. Change from Week 16 in ASAS -Health Index  
8. Change from Week 16 in FACIT -Fatigue  
Analyses of secondary efficacy variables  1 and 3- 6 at each time point will 
be similar to the analyses of the primary efficacy variable.   
Secondary efficacy variables 2, 7, and 8 will be analyzed at each time point by [CONTACT_90170], Week 16 value, TNF -
alpha inhibitor status (naive, inadequate responder), and baseline body 
weight as explanatory variables.  The least squares means of the treatment 
groups, least squares mean difference, and 95% confidence interval for 
the difference will be reported, based on the fitted linear model.  Missing data will be imputed using the last -observation -carried -forward method.  In 
an additional analysis, missing data will be imputed using multiple 
imputation.  
Analyses of the primary and secondary efficacy variables will be based on the Full Analysis Set.  
The assessment of safety will be based mainly on the frequency of adverse 
events and laboratory data.  
 For safety analyses, the Enrolled Set will be 
used for Treatment Period 1, and the Safety Set will be used for Treatment Period 2. 
The sample size was calculated based on the primary efficacy variable 
(i.e., ASDAS inactive disease response) at Week 52 for the Full Analysis 
Set.  The expected ASDAS inactive disease response rates for 
secukinumab 300 mg and 150 mg treatment groups at Week 52 are 20% 
and 10%, respectively (corresponding to an odds ratio of 2.25), partly 
based on results from AIN457F2310 (MEASURE 2) study.  With 
approximately 97 patients in each treatment group (total of 194 
randomized patients), one will be able to estimate the difference between ASDAS inactive disease response rates of the two treatment groups at 
Week 52 with a “margin of error” (half -width of confidence interval) of 10% 
(corresponding to a standard error of 5%) for a two-sided 95% confidence 
interval  (
Julious and Patterson, 2004; nQuery Advisor 7.0).  
It is expected that the study will need to enroll approximately 270 patients 
for Treatment Period 1, to randomize approximately 194 patients who do 
not achieve ASD AS inactive disease status at Week 16 (inadequate 
responders).  This assumes that 10% of the 270 enrolled patients will 
discontinue during Treatment Period 1; among the remaining enrolled 
[COMPANY_001]  Confidential  Page 17  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
patients, it is assumed that approximately 10% will be responders, 8 0% 
will be inadequate responders, and 10% will be non -responders.  
Key words  Ankylosing spondylitis, ASDAS inactive disease, sacroiliitis, secukinumab  
[COMPANY_001]  Confidential  Page 18  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
1 Introduction  
1.1 Background 
Ankylosing spondylitis (AS) is a chronic inflammatory disease which belongs to a group of 
conditions known as spondyloarthritides. AS is mainly characterized by [CONTACT_90171], but it also affects peripheral joints,  entheses and 
extraarticular organs. A significant proportion of patients may present with associated extraarticular manifestations such as uveitis, psoriasis, inflammatory bowel disease (IBD), cardiovascular and pulmonary abnormalities. Generalized osteoporosis, as well as regional osteopenia are common in AS patients and predispose them to non- traumatic fractures in spi[INVESTIGATOR_90152] (male). The presence of the HLA -B27 human leukocyte antigen is 
strongly associated with AS: 90–95% of patients with AS who have European ancestry carry this marker. AS affects up to 1.1% of the population, is associated with significant morbidity and disability, and thus constitutes a major socioeconomic burden.  
First-line medication of mild AS consists of non -steroidal anti- inflammatory drugs (NSAIDs). 
Treatment of NSAID -refractory AS is hampered by [CONTACT_90172] -rheumatic drugs (DMARDs), including methotrexate (MTX). As an 
exception, peripheral arthritis ass ociated with AS may respond to sulfasalazine and 
methotrexate. Tumor necrosis factor (TNF) blocking agents were successfully added to the 
armamentarium to treat AS (Braun 2002) and subsequently demonstrated prolonged efficacy up to eight years of follow -up ( Baraliakos 2011). However, upon discontinuation of TNF 
blockers the disease relapses quickly ( Baraliakos 2005), indicating that the inflammatory 
process may have only been inhibited but not completely abolished.  
Patients with AS report chronic and extensive sleep disturbance due to pain and stiffness during the night ( Leverment 2017).  Often patients get out of bed and walk around during the night to 
reduce pain and stiffness, which can lead to daytime fatigue ( Rudwaleit 2006).  In AS patients 
poor quality sleep is strongly correlated with increased pain, lower quality of life, higher depressed mood, higher disease activity and redu ced physical function ( Batzman 2013). 
Treatment with anti -TNF golimumab has been shown to significantly reduce sleep disturbances 
in AS patients over 14 weeks as assessed by [CONTACT_63496] ( Deodhar 2010).  The effect of 
secukinumab on AS related sleep disturbance has not yet been studied.  Additionally, there is a general lack of data to investigate associations between sleep disturbance and daytime fatigue levels in AS.  
Although studies have been conducted with subjective measures of sleep in patient with AS, 
there have been limited assessments with quantitative measure of sleep disturbance, such as with polysomnography. A recent polysomnography study of 59 patients with AS demonstrated impairments in sleep architecture between patients on NSAID therapy, with improvements seen in total sleep time and sleep efficiency by [CONTACT_90173] (In 2016).  Another valid objective measure of sleep, and daytime activity, is actigraphy that measures activity with a wearable accelerometer, a digital sensor that can be worn on the wrist that measures the accelerations of the device in motion along reference axes. Actigraphic assessment data from an accelerometer typi[INVESTIGATOR_90153] (collected in units of ms
-1s-1) with respect to time (Chen 2005), with a typi[INVESTIGATOR_90154] a rate 
of 32- 100 Hz (cycles per second). Acceleration data is condensed and stored in the device in 
[COMPANY_001]  Confidential  Page 19  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
fixed ‘epochs’ of time. Actigraphic assessment of sleep disruption and daytime activity is less 
burdensome for patients than traditional daily assessments and much less intrusive than polysomnography while providing data that is not effected by [CONTACT_90174].   While 
untested in patients with AS, actigraphy has been successfully used in prospective interventional studies to assess the impact of pharmacological treatment on both sleep and daytime physical ac tivity, in atopic dermatitis ( Nemoto 2016), heart failure (Redfield 2015), 
and osteoarthritis ( Trudeau 2015).  
Secukinumab (AIN457) is  a high -affinity human monoclonal anti -human antibody that 
neutralizes IL -17A activity. IL -17A is the key cytokine in the Th17 and innate immune 
pathways which is thought to be an important mediator of autoinflammation. Secukinumab is currently approved by [CONTACT_90175], active psoriatic 
arthritis, and active ankylosing spondylitis ( Cosentyx
® package insert ).  
Secukinumab has been previously evaluated in active AS in the MEASURE 1 and MEA SURE 
2 studies of 590 patients with AS ( Baeten et al., 2015 ), demonstrating the efficacy of 
secukinumab 150 mg (S.C.) versus placebo on ASAS20 at Week 16 in both studies. Inconsistent 
results were seen with 75  mg, and 300 mg was not included as a dosage in these two pi[INVESTIGATOR_41961]. As such, secukinumab received initial FDA approval for only 150 mg of 
secukinumab every 4 weeks with or without loading in the treatment of active ankylosing spondylitis. A subsequent Phase III study (MEASURE 3) was conducted that included a 300  
mg dose group, which demonstrated a significant difference from placebo on ASAS20 at Week 16, however the efficacy did not clinically differ from the 150 mg dose group at Week 16. Of 
note, this study involved an intravenous loading regimen of 10 mg/kg secukinumab at Week 0, 2 and 4, followed by s.c. dosing every 4 weeks of 150 mg or 300 mg. This intravenous loading 
regimen conferred initially higher concentrations of secukinumab such t hat a meaningful 
assessment between the 300 mg and 150 mg doses would not be attainable at the Week 16 
primary analysis time point. However, at Week 52 and beyond, presumably when the pharmacokinetic influence of the intravenous load had waned, evaluation of higher hurdle efficacy measures (e.g., ASDAS -inactive disease, ASAS Partial Remission), revealed higher 
efficacy responses for [ADDRESS_99371] not 
met an a prioi  established target clinical response, such as a non -response threshold, or a high-
response target, such as disease remission or a com parable analogue. As 300 mg is an available 
dose with an established safety profile comparable to 150 mg in both moderate to severe plaque psoriasis and active psoriatic arthritis and has demonstrated clinically meaningful differences compared to 150 mg on  certain clinical measures (e.g., PASI, ACR50, ACR70), and patient 
subgroups (anti -TNF inadequate responders), it is appropriate to pursue the study of 300 mg in 
AS.       
[COMPANY_001]  Confidential  Page 20  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
As of 25-Jun- 2017, over 11,[ADDRESS_99372] investigated various indications 
(Rheumatoid Arthritis (RA), AS, Psoriatic Arthritis (PsA), psoriasis, multiple sclerosis, uveitis, Crohn’s disease, dry eye syndrome, polymyalgia rheumat ica, diabetes mellitus) at doses 
ranging from single and multiple doses of 0.1 mg/kg to 30 mg/kg i.v. and [ADDRESS_99373] Investigator’s Brochure (IB) for a more detailed review of the risk:benefit profile of secukinumab which supports the clinical development for the treatment of AS patients with 
secukinumab. 
 
1.2 Purpose 
The purpose of this study is to estimate the difference in clinical response between 300 mg and 
150 mg of secukinumab at Week 52, which follows randomization to dose escalation at Week 16 for patients with Ankylosing Spondylitis who  inadequately respond to open- label 
secukinumab 150 mg. This study will also investigate the association between treatment and sleep disturbances, as well as daytime activity patterns.  
2 Study objective and endpoints 
2.1 Objectives and related endpoints  
Table 2-1 Objectives and related endpoints  
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary objective(s)  
1. To estimate the difference between secukinumab 300 mg and secukinumab 150 
mg blinded treatment groups at Week 52 
based on the proportion of subjects achieving ASDAS inactive disease (< 1.3) status who 
did not meet ASDAS inactive disease criteria 
at Week 12 and Week 16.  1. The primary efficacy variable is the ASDAS 
inactive disease response (yes, no).  The 
primary analysis time point is at Week 52.  
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
1. To estimate the difference between 
secukinumab 300 mg and secukinumab 150 
mg blinded treatment groups at Week 52 
based on the proportion of subjects achieving 
a ASDAS clinically important improvement 
from their Week 16 ASDAS score (reduction in ASDAS  ≥  1.1 from Week 16)  
2. To estimate the difference between secukinumab 300 mg and secukinumab 150 mg blinded treatment groups at Week 52 
based on the change from Week 16 in the 1. Reduction in ASDAS ≥  1.1 from Week 16 
(yes, no)  
2. Change from Week 16 in total BASDAI  
3. BASDAI50 response (yes, no)  
4. ASAS20 response (yes, no)  
5. ASAS40 response (yes, no)  
6. ASAS partial remission (yes, no)  
7. Change from Week 16 in ASAS -Health Index  
[COMPANY_001]  Confidential  Page 21  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Objective(s)  Endpoint(s)  
total Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI)  
3. To estimate the difference between 
secukinumab 300 mg and secukinumab 150 mg blinded treatment groups at Week 52 
based on the proportion of subjects achieving 
BASDAI50 response  8. Change from Week 16 in FACIT -Fatigue  
 
[COMPANY_001]  Confidential  Page 22  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Objective(s)  Endpoint(s)  
Secondary Objective(s)  Endpoint(s) for secondary objective(s)  
4. To estimate the difference between 
secukinumab 300 mg and secukinumab 150 
mg blinded treatment groups at Week 52 
based on the proportion of subjects achieving an Assessment of Spondyloarthritis 
International Society criteria 20 response 
(ASAS20)  
5. To estimate the difference between secukinumab 300 mg and secukinumab 150 mg blinded treatment groups at Week 52 
based on the proportion of subjects achieving 
ASAS40 response  
6. To estimate the difference between 
secukinumab 300 mg and secukinumab 150 
mg blinded treatment groups at Week 52 based on the proportion of subjects achieving 
ASAS partial remission (a value not above 2 
units in each of the four main domains on a scale of 10)   
7. To estimate the difference between secukinumab 300 mg and secukinumab 150 mg blinded treatment groups at Week 52 
based on change from Week 16 in the total 
score of ASAS Health Index (ASAS-HI)   
8. To estimate the difference between 
secukinumab 300 mg and secukinumab 150 
mg blinded treatment groups at Week 52 
based on change from Week 16 in the total 
score of FACIT -Fatigue  
9. The overall safety and tolerability of 
secukinumab   
 
 
  
 
 
 
  
 
  
 
  
 
 
 
 
  
 
 

[COMPANY_001]  Confidential  Page 23  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 

[COMPANY_001]  Confidential  Page 24  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
[ADDRESS_99374] an 
3.1 Study design   
This study will use a randomized, double- blind, parallel -group design, multicenter design.  
There are 3 study periods:   
 
1. Screening:  A screening period will take place over two separate visits, with the first 
visit used to assess eligibility and to washout prohibited medications (up to 11 weeks). 
The second screening visit, which will occur at a minimum of 2 weeks prior to the baseline visit for all patients.  
 
  Note: Patients that do not require a washout, and who satisfy all 
inclusion and none of the exclusion criteria  at the first screening visit can initiate 
the second screening visit one week after their first screening visit.  
2. Treatment Period 1:  Patients who meet all of the inclusion criteria and none of the 
exclusion criteria will have a Baseline Visit performed to start Treatment Period 1.  During this 16-week period, all patients will receive open- label secukinumab 150  mg 
[1 x 1.0mL s.c.] at baseline, Weeks 1, 2, 3, 4, 8, and 12.   
 
At Week 16, patients will be placed into one of the following groups: 
 
a. Responders:  Patients achieving ASDAS inactive disease (total score < 1.3) at both 
Week 12 and Week 16  and who do achieve a decrease (improvement) fr om baseline in 
total ASDAS score at both Week 12 and Week 16 .  
b. Inadequate responders:  Patients who have active disease, defined as an ASDAS total 
score of ≥1.3 at either Week 12 or Week 16, and who do achieve a decrease 
(improvement) from baseline in total ASDAS score at both Week 12 and Week 16.   
c. Non-responders: Patients who exhibit no change or an increase (worsening) from 
baseline in total ASDAS score at either  Week 12 or  Week 16  
Note:  To mi nimize patient burden, at the Week [ADDRESS_99375] varied little between 
Week 12 and Week 16 or in previous studies of secukinumab in active AS.      
3. Treatment Period 2:   Upon completion of the Week 16 visit,  
 
a. Responders will enter Treatment Period 2 and continue to receive secukinumab 150 
mg every 4 weeks through Week 48 as well as one matched placebo dose (s.c. 
injection) to maintain the integrity of the blind for the randomized Inadequate Responder group.  
 

[COMPANY_001]  Confidential  Page 25  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
b. Inadequate r esponders will enter Treatment Period 2 and will be randomized  
(1:1, double-blinded) to secukinumab 300 mg or secukinumab 150 mg very 4 weeks 
through Week 48. Subjects will know that they are on secukinumab, but will be blinded to dose, as they will not know whether they are receiving 150 mg or 300 mg. 
 
c. Nonresponders will be discontinued from the study at Week 16.  
The only condition that will be placed on enrollment targets is that no less than 60% of patients (162 patients) are TNFα inhibitor naive (or, no more than 40% of patients are TNF -IR). In 
theory the percentage of TNFα inhibitor naive patients could reach 100%, although that is not anticipated.  
Patien ts may discontinue the study at any time. If rescue treatment with prohibited medications 
 occurs, patients will be discontinued from the study and should 
return for an End of Study Visit  (see Table 6 -1). The End of Study Visit should be scheduled 
approximately four weeks after the last study treatment, and should be performed before any 
new treatment is initiated. After the End of Study Visit, any SAEs that occur in the following [ADDRESS_99376] population will be described in more detail in Section 4 below.  The two visit  Screening Period is designed to allow for both (1) washout of prohibited 
medications, and  
-13 to ≥3

[COMPANY_001]  Confidential  Page 26  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
 
   
 
T
he randomized, blinded, parallel -group design used in this study is based on the primary focus 
of this study, which is to estimate the difference in clinical response between either remaining on 150 mg or escalating to 300 mg of secukinumab after not achieving a measured state of 
inactive disease at the Week 12 and Week 16 time points. The responder status at Week 12 and Week 16, as well as the primary objective at Week 52 is determined with the validated ASDAS clinical scoring measure of disease activity status which will establish patients who score within the “inactive disease” classificatio n of this measure (a total score of <  1.3). Week 52 has been 
selected as the primary analysis time point to allow sufficient time (36 weeks) for a clinical response to be observed following dose escalation to 300 mg at Week 16 vs those patients who 
remain on 150 mg for the entire 52-week period.  
Following the Week 16 visit, randomized inadequate responder patients and investigators will 
be blind to the dose of secukinumab through the use of a matched placebo injection (identical in appearance) in the 150  mg s.c. group. The blinding of the secukinumab treatments (150 mg 
or 300 mg) will allow for an evaluation of a potential dose -response of the 150 mg and 300 mg 
secukinumab doses on both efficacy and safety outcomes.  
Responder patients, those who achieve AS DAS inactive disease at Week 12 and Week 16, will 
continue on secukinumab 150 mg to evaluate the longer -term treatment response up to Week 
52. To support the integrity of the blind for the randomized inadequate responder group, the 
responder patients will also be dose blinded between Week 16 and Week 48 by [CONTACT_26777] a single matching placebo injection to their secukinumab 150 mg injection. Thus, all responder and inadequate responder patients will be blinded to dose and will receive two matched injections e very 4 weeks. While the responder group is not the primary focus of this study, this 
subgroup will provide meaningful exploratory analyses of the clinical characteristics and duration of response in patients who achieve a high- level efficacious response to  secukinumab 
at Week 16.  
The population of non- responders, expected to be low in number, will be discontinued from the 
study at Week 16 as these patients would be considered a primary failure of therapy. Non-
responders, by [CONTACT_90176], or a worsening of disease activity after 
16 weeks of treatment are not expected to improve with a dose escalation, and thus are to terminate the study to seek alternative treatments options that may benefit their disease.   
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment   
The secukinumab dosing regimens in this study are based upon the currently approved dose for active ankylosing spondylitis, which is 150 mg s.c. every 4 weeks (without or with a loading 
regimen of 150 mg at Weeks 0, 1, 2, 3, and 4.  

[COMPANY_001]  Confidential  Page 27  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
The rationale for the use of [ADDRESS_99377] that 300 mg is an approved dose to treat patients with moderate -to-severe plaque psoriasis and active psoriatic arthritis. In psoriatic arthritis, it is 
labeled as an escalation dose for patients who remain with active disease while on a 150 mg dosing regimen. In both the psoriasis and psoriatic arthritis clinical studies, several measures demons trated higher responses with 300 mg versus 150 mg, including the clearance of psoriatic 
plaques, as well as in patients who were previous inadequate responders to anti -TNFα therapi[INVESTIGATOR_014]. 
Further, 300 mg treatment groups demonstrated a comparable safety profile to 150 mg every 4 weeks. ( Langley 2014, Mease 2015 ).  
This study will evaluate whether a higher dose of secukinumab will have an effect on subjects with AS, specifically signs and symptoms of AS and the achievement of state of inactive disease based on the ASDAS measure.  The duration of treatment of initial open -label 150 mg for 16 
weeks is based on Week 16 being the primary analysis time point for the previous Phase 3 secukinumab studies in AS. While statistical separation on the ASAS20 measure occurs as early as Week 1, greater responses are seen out to Week 16 and beyond ( Baeten et al., 2015). In 
addition, patients will receive the loading regime of weekly dose of secukinumab [ADDRESS_99378] over the long -term extension of studies, reveal a steady incline 
in response on several measures, particularly for BASDAI and ASAS40, over the Week 16 to 
Week 52 to Week 104 timeframes ( Marzo -Ortega 2017). Therefore, the 36 -week duration of 
Treatment Period 2 will provide a sufficient period of time to observe any treatment differences 
between the 300 mg and 150 mg groups. 
 
3.4 Rationale for choice of comparator  
This study does not include a placebo arm. Efficacy in terms of signs and symptoms is well 
established for secukinumab 150 mg for patients with active AS. Moreover, a placebo cohort 
would not be deemed ethically justifiable for this 1 -year study, considering AS is known to be 
a chronic progressive disease with structural damage.  
3.5 Purpose and timing of interim analyses/design adaptations  
Not applicable. 
3.[ADDRESS_99379] been demonstrated in the treatment of psoriasis ( Langley 2014; Thaçi 2015), as well as significant difference from 
placebo in the treatment of joint pain, swelling, health -related quality of live, and radiographic 
progression in PsA (Mease 2015 ; McInnes 2015 ; van der Heijde, 2016 ) and AS ( Baeten et al 
2015;  Braun 2016).  
[COMPANY_001]  Confidential  Page 28  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
The large safety dataset  of secukinumab across indications involving over 9,[ADDRESS_99380] frequently reported adverse events (AEs) are non -
seriou s mild to moderate infections, mainly upper respi[INVESTIGATOR_90155]. In addition, there was an increase in localized mucosal or cutaneous candidiasis with secukinumab compared with placebo, but the cases were gener ally mild or 
moderate in severity, non- serious, and responsive to standard treatment and did not require 
discontinuation of secukinumab. There was also a small increase in neutropenia cases with secukinumab compared with placebo. Most cases were mild to moderate, transient and reversible and without a temporal relationship to infections. Common Toxicity Criteria (CTC) AE grade 3 neutropenia (< 1.0- 0.5 x 109/L) was uncommonly observed with secukinumab. 
Hypersensitivity reactions include urticaria and rare ev ents of anaphylactic reaction to 
secukinumab have also been observed in clinical studies.  
Taking  into  account  the  individual  risks  as  outlined  above,  the  expected  risk  profile  of secukinumab from a mechanism of action perspective is anticipated to be similar or improved compared to the approved inflammatory cytokine -targeting therapi[INVESTIGATOR_014]. The risk to patients in 
this  trial  will  be  minimized  by  [CONTACT_90177],  close  clinical monitoring and extensive guidance to the investigators, provided in the current version of the IB. From the standpoint of the overall risk -benefit assessment, current trial with secukinumab 
is justified.  
[ADDRESS_99381] of male and female patients, ≥ 18 years of  age with a clinical 
diagnosis of moderate to severe AS fulfilling the Modified [LOCATION_001] criteria for AS  
 and with moderate to severe disease despi[INVESTIGATOR_90149] / non-
biologic DMARDs and/or anti- TNFα therapy.  
Patients must have a history of active AS, as measured by [CONTACT_90178]:  
• Total BASDAI of ≥  4 on a NR S of 0-10 at baseline 
• Spi[INVESTIGATOR_90150] #2 of ≥  4 on a NRS of 0-10 at baseline 
• Total back pain ≥  4 on a NRS  of 0-10 at baseline  
The study aims to enroll approximately 270 patients at approximately 82 centers in the United 
States.  Since a 25% screen failure rate is expected, approximately [ADDRESS_99382] been randomized will not be replaced. 
4.1 Inclusion Criteria  
Patients/subjects eligible for inclusion in this study must fulfill all of the following criteria:  
 
1. Patient must be able to understand and communicate with the investigator and comply 
with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed  
2. Male or non-pregnant, non- lactating female patients at least 18 years of age  

[COMPANY_001]  Confidential  Page 29  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
3. Diagnosis of moderate to severe AS with prior documented radiologic evidence (x -ray or 
radiologist’s report) fulfilling the Modified [LOCATION_001] criteria for AS   
4. Active AS assessed by [CONTACT_90168] ≥ 4 ( NRS of 0- 10) at baseline  
5. Spi[INVESTIGATOR_90150] #2 of ≥ 4 ( NRS of 0-10) at baseline 
6. Total back pain of ≥  [ADDRESS_99383] 4 weeks 
prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if 
withdrawn for intolerance, toxicity or contraindications  
8. Patients who are regularly taking NSAIDs (including COX- 1 or COX- 2 inhibitors) as part 
of their AS therapy are required to be on a stable dose for at least [ADDRESS_99384] been on a TNFα inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 
[ADDRESS_99385] previously been on a TNFα inhibitor will be allowed entry into s tudy 
after appropriate wash -out period prior to their Baseline Visit: 
• 4 weeks for Enbrel® (etanercept) – with a terminal half -life of 102 ± 30 hours (s.c. 
route) 
• 8 weeks for Remicade (infliximab) – with a terminal half -life of 8.0 -9.5 days (i.v. 
infusion) 
• 11 weeks for Humira (adalimumab) – with a terminal half -life of 10 -20 days (average 2 
weeks)(s.c. route)  
• 11 weeks for Simponi (golimumab) – with a terminal half- life of 11 -14 days  
• 11 weeks for Cimzia (certolizumab) – with a terminal half-life of 14 days  
11. Patients taking MTX (≤ 25 mg/week), sulfasalazine (≤ 3 g/day), or leflunomide (≤20 
mg/day) are allowed to continue their medication and must have taken it for at least [ADDRESS_99386] to be on a stable dose of ≤ 10 mg/day 
prednisone or equivalent for at least 2 weeks before baseline 
4.2 Exclusion Criteria   
Patients fulfilling any of the following criteria during the Screening Period or at the Baseline Visit are not eligible for inclusion in this study. No additional exclusions may be applied by [CONTACT_1275], in order to ensure that the study population will be representative of all eligible patients/subjects.  

[COMPANY_001]  Confidential  Page 30  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
1. Patients with total ankylosis of the spi[INVESTIGATOR_050]  
2. Use of other investigational drugs within [ADDRESS_99387] magnetic resonance imaging (MRI) with evidence of 
ongoing infectious or malignant process, obtained within 3 months prior to screening and 
evaluated by a qualified physician  
5. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17, IL-12/23, or the IL-[ADDRESS_99388] taken more than one anti -TNFα agent  
7. Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline  
8. Any therapy by [CONTACT_90169]- articular injections (e.g. corticosteroid) within 4 weeks before 
baseline  
9. Previous treatment with any cell- depleting therapi[INVESTIGATOR_90156] -
CD20, investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti- CD3, anti-
CD19)  
10. Patients taking high potency opi[INVESTIGATOR_2467] (e.g., methadone, hydromorphone, 
morphine) 
11. Active systemic infections during the last two weeks (exception: common cold) prior to 
baseline  
12. Active ongoing inflammatory diseases other than AS that mig ht confound the evaluation 
of the benefit of secukinumab therapy, including inflammatory bowel disease or uveitis 
13. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions which in the opi[INVESTIGATOR_90157]/or places the patient at unacceptable risk for participation in an immunomodulatory therapy 
14. Significant medical problems or diseases, including but not limited to the following: 
uncontrol led hypertension, congestive heart failure ([LOCATION_001] Heart Association status of 
class III or IV), uncontrolled diabetes, or very poor functional status unable to perform 
self-care 
15. History of clinically significant liver disease or liver injury as indicate d by [CONTACT_90179] (AST), SGPT (ALT), alkaline phosphatase, or serum bilirubin. The Investigator should be guided by [CONTACT_4868]: 
• Any single parameter may not exceed 2 x upper limit of normal (ULN). A single paramete r elevated up to and including [ADDRESS_99389] prior to enrollment/ baseline, to rule out lab 
error  
16. Serum creatinine level exceeding 2.0 mg/dL (176.8 µmol/L) at screening  
17. Screening tota l WBC count < 3,000/μL, or platelets < 100,000/μL or neutrophils 
<1,500/μL or hemoglobin < 8.5 g/dL (85 g/L)  
[COMPANY_001]  Confidential  Page 31  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
18. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C at 
screening  
19. History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past [ADDRESS_99390] been 
removed) 
20. Patients with other clinically significant conditions (not associated with the study indication) which in the judgement of the investigator might interfere with the assessment of this study, or puts the s ubject at increased risk  
21. Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability or lack of access to veins) 
22. Inability or unwillingness to receive injections with the PFS  
23. Any medical or psychiatric condition which, in the Investigator’s opi[INVESTIGATOR_1649], would preclude 
the participant from adhering to the protocol or completing the study per protocol  
24. Donation or loss of [ADDRESS_99391] 6 months before baseline  
26. Patients who know they will be unable to complete 1 year of study treatment period 
27. Administration of live vaccines during the study period or 6 weeks prior to ba seline  
28. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by [CONTACT_5640] a positive purified protein derivative ([COMPANY_003]) skin test (the size of induration will be measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5 mm or according to local practice/guidelines) or a positive central laboratory TB blood screening test as indicated in the assessment schedule in Table 6-1. 
Patients with a positive test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment according to local country guidelines must hav e been initiated  
29. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test 
30. Women of child- bearing potential, defined as all women physiologically capable of 
becoming pregnant, are excluded from the study unless they are using highly effective 
methods of contraception during dosing and for [ADDRESS_99392] at Screening Visit 2, regardless of the method of contraception being used.  Highly effective contraception methods include:  
• Total abstinence (when this is in line with the preferred and usu al lifestyle of the 
subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy or tubal ligation at least six weeks before taking study 
[COMPANY_001]  Confidential  Page 32  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
drug. In case of oophorectomy alone, only when the reproductive status of the woman 
has been confirmed by [CONTACT_104] 
• Male sterilization (at lea st 6 months prior to screening). For female subjects on the study, 
the vasectomized male partner should be the sole partner for that subject  
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps).  
• Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <  
1%), for example h ormone vaginal ring or transdermal hormone contraception.  In case 
of use of oral contraception, women should have been stable on the same pi[INVESTIGATOR_6522] a minimum of 3 months before taking study drug. 
NOTE:  Women are considered post -menopausal and not of child bearing potential if they have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6592]. 
5 Treatment 
5.1 Study treatment  
5.1.1 Investigational and control drugs 
[COMPANY_001] will supply the following study treatments in packaging of identical appearance: 
• Secukinumab 150 mg provided in 1.0 mL in a prefilled syringe (PFS) for s.c. injection. 
• Secukinumab placebo provided in 1.0 mL a PFS for s.c. injection (for matching 150 mg 
dose to blind 300 mg dosing) 
NOTE:  The PFS are packed in an open -label fashion from baseline through the Week 12 visit. 
Beginning Week 16, the PFS are packed in a double -blinded fashion for t he remainder of the 
study. 
5.1.2 Additional treatment   
No additional treatment beyond investigational drug and control drug are included in this trial. 
5.2 Treatment arms  
Treatment Period 1  
[COMPANY_001]  Confidential  Page 33  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Once screening has been completed and patients have met the eligibility crit eria, all patien ts 
will undergo 16 weeks of open- label treatment with secukinumab 150 mg s.c. self -administered 
at the site at baseline, Weeks 1, 2, 3, 4, 8, and 12. 
All assessments at the scheduled visit will be performed before the patients receive the 
injection with the appropriate study medication for that visit.  
At Week 12 and Week 16, all patients will be assessed for achieving the ASDAS inactive disease (<1.3) status, as well as for an inadequate response or a non -response.  Patients will then 
be divided into three groups: 
 
1. Responders: Patients achieving ASDAS inactive disease (total score < 1.3) status at Week 
12 and Week 16 and who do achieve a decrease (improvement) from baseline in total ASDAS score at both Week 12 and Week 16.    
2. Inadequate responders: Patients who have active disease, defined as an ASDAS total score of ≥1.3 at either Week 12 or Week 16 , and who do achieve a decrease (improvement) 
from baseline in total ASDAS score at both Week 12 and Week 16.    
3. Non-responders: Patients who exhibit no change or an increase (worsening) from baseline 
in total ASDAS score at either Week 12 or Week 16  
 Treatment Period 2 (Responders and Non -responders)  
Responders:  Patients achieving responder status will enter Treatment Period 2 and continue to 
receiv e 150 mg s.c. (one s.c. injection of secukinumab 150 mg) at Weeks 16, 20, 24, 28, 32, 
36, 40, 44, and 48, as well as one matched placebo dose (s.c. injection) to maintain the integrity of the blind for the randomized Inadequate Responder group. This Respon der group 
will be evaluated for maintenance of ASDAS inactive disease while remaining on 150 mg of secukinumab. All assessments at the scheduled visit will be performed before the patients receive the injection with the appropriate study medication for tha t visit.  
NOTE:  To minimize patient burden, at the Week [ADDRESS_99393] varied little be tween Week 
12 and Week 16 in previous studies of secukinumab in active AS.  
Non-responders:  Nonresponders will terminate the study at Week 16.    
 
Treatment Period 2 (Inadequate Responders)  
Inadequate responders will be randomized via the Interactive Respo nse Technology (IRT) 
system in a 1:1 ratio to receive either secukinumab 300 mg (two s.c. injections of the 150 mg 
dose) or secukinumab 150 mg (one s.c. injection of the 150 mg dose and one s.c. injection of placebo) at Weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.  
[COMPANY_001]  Confidential  Page 34  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Patients will self -administer all secukinumab doses up to Week [ADDRESS_99394], continued assistance by [CONTACT_90180]. All assessments at 
the scheduled visit will be performed before the patients receive the injection with the 
appropriate study medication for that visit.  
5.3 Treatment assignment and randomization  
At Baseline through Week 12, the Interactive Response Technology (IRT) system will be used 
at each visit to dispense open- label treatment to enrolled patients.  The system will specify 
unique medication numbers that will correspond to open- label treatment to be dispensed.  
Responders:  At W eek 16 through Week 48, the IRT system will be used at each visit to 
dispense treatment and matching placebo to ASDAS -inactive disease responders.  The system 
will specify unique medication numbers that will correspond to treatment to be dispensed.  
Inadequate Responders:  At Week 16, all ASDAS -inactive disease inadequate responder 
eligible patients will be randomized via IRT to one of the treatment groups in a ratio of 1:1 (secukinumab 300 mg or secukinumab 150 mg). The IRT system will assign a randomization  
number to the subject, which will be used to link the subject to a treatment group in the system and will specify unique medication numbers for treatment to be dispensed to the subject. The randomization number will not be communicated to any of the site staff. The IRT system will be used at each visit from Week [ADDRESS_99395] will be produced by [CONTACT_90181] a validated system that automates the random assignment of medication numbers to packs containing the investigational drug(s).  
Randomization will be stratified by [CONTACT_51004] -alpha inhibitor status (naive, inadequate 
responder).  The stratification ensures balanced allocation of patients to treatment groups within 
the TNF -alpha inhibitor statu s strata.    
The randomization scheme for patients will be reviewed and approved by a member of the 
[COMPANY_001] Biometrics group.   
 
5.4 Treatment Blinding  
Patients, investigators/site staff, persons performing assessments, and [COMPANY_001] study personnel 
will remain blinded to individual treatment assignment from the time of randomization (Week 16) for the inadequate responder group and responder group until the final database lock using the following methods:  
1. Randomization data will be kept strictly confiden tial until the time of unblinding, and will 
not be accessible  by [CONTACT_90182]: 
[COMPANY_001]  Confidential  Page 35  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
• Specific vendors whose role in trial conduct requires their unblinding (e.g., IRT 
system)  
• Drug Supply Management (DSM); 
2. The identity of secukinu mab and placebo prefilled syringes (PFS) will be  concealed  by 
[CONTACT_90183], labeling, schedule of administration,  and appearance.  
There will be a database lock after all patients have completed the Week [ADDRESS_99396] emergencies (see Section 5.5.9) and at the 
conclusion of the study. 
5.[ADDRESS_99397] is uniquely identified in the study by a combination of his/her four digit center number and three digit subject number. The center number is assigned by [CONTACT_5359]. After the subject has signed the ICF, the investigator or his/her staff will 
contact [CONTACT_90184]. The site must select the CRF book with a matching Patient Number from the EDC system to enter data.  At each site, the subjects are numbered sequentially.  (e.g. the first subject is assigned subject number 001, and subsequent patients are assigned consecutive numbers; the second subject is assigned subject number 002; the third subject is assigned subject number 003). Once assigned to a subject, a subject number will not be reused. If the subject fails to be randomized for any reason, the IRT system must be notified within 2 days and the reason for not being randomized will be entered on the Screening Phase Disposition Form within the eCRF. The appropriate eCRF(s) pages should also be completed. 
5.5.2 Dispensing the study drug 
All doses of study treatment will be self -administered by [CONTACT_90185] (or at home) 
after they have received training by [CONTACT_90186]- administer.  
The study treatment packaging has a 2- part label. A unique medication number is printed on 
each part of this label, which corresponds to placebo or active treatment. Investigator staff will 
identify the study treatment packages to dispense to the subject by [CONTACT_90187]. Immediately before dispensing the package to the subject, detach the outer part of the label from the packa ging and affix it to the source document (Drug 
Label Form) for that subject’s unique subject number. 
5.5.3 Handling of study and additional treatment  
[IP_ADDRESS] Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly, and kept in a secured location to which only the investigator and designees have access. Upon receipt, all study treatment should be stored according to the instructions 
[COMPANY_001]  Confidential  Page 36  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
specified on the labels. Clinical supplies are to be dispensed only in accordance with the 
protocol. 
Medication labels will be in English and comply with legal requirements in the U.S. They will 
include storage conditions for the study treatment but no information about the patient except for the medication number.  
The PFS (150 mg active/placebo) sealed in their outer box must be stored in a locked refrigerator between 2°C and 8°C (36°F and 46°F) and protected from light. They m ust be 
carefully controlled in accordance with regulations governing investigational medicinal products and local regulations. 
The Investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability log.  Monitoring of drug accountability will be performed by 
[CONTACT_90188].  
At the conclusion of the study, and as appropriate during the course of the study, the Investigator will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the Investigator folder at each site.  
Destruction of the unused drug should be done according to loc al requirements and after 
approval by [CONTACT_90189].  
[IP_ADDRESS] Handling of additional treatment  
5.5.[ADDRESS_99398] 
been completed. Qualified staff will administer the injection only to those patients who are not able to self -administer the PFS injection. Detailed instructions on the self- administration of the 
study treatment will be described in the Instructions For Us e (IFU) and provided to each subject.  
The first study treatment administration will occur at the Baseline Visit after inclusion/exclusion criteria have been confirmed, all study scheduled assessments have been performed , and the scheduled blood samples have been drawn. 
The patien t will be instructed by [CONTACT_7893], utilizing the IFU, on how to self -inject via PFS. 
Patients will be asked to raise any questions, if they have any, and then to proceed with self - 
injection. Self- injection will take place und er the supervision of a site staff member. At the 
Week [ADDRESS_99399], continued 
assistance by [CONTACT_90190].  
Study treatment will be administered weekly following the baseline dose (Weeks 1, 2, 3, and 4) and every 4 weeks thereafter ( at Week 8 until Week 48). 
All dates and times of injections self -administered by [CONTACT_90191]. Immediately before dispensing the drug package to the subject, detach the outer part of the label from the packaging and affix it to the source document (Drug Label Form) for that subject’s  unique subject number.  
[COMPANY_001]  Confidential  Page 37  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
The Investigator should promote compliance by [CONTACT_90192]’s safety and the validity of the study. The subject should be  instructed to contact [CONTACT_18611]/she is unable for 
any reason to attend a study visit as scheduled or if he/she is unable for any reason to take the study treatment as prescribed.   For patients unable to travel to the clinic for their study vi sit, 
flexible study visits (home nursing study visits) and telemedicine/telephone visits with direct to patient shipment of study drug are alternative options for all post- Baseline study visits.  For 
more information regarding flexible study visits, please  refer to the Site Manual for Home Visits 
(Flexible Study Visits).  
[IP_ADDRESS] Administration 
Secukinumab Solution for Subcutaneous Injection (active or placebo, respectively) will be provided in prefilled syringes (PFS).  
Single syringes will be packed in individual boxes. The boxes containing the safety prefilled syringes with study treatment solution should be kept at 2 to 8°C (36°F and 46°F) and protected from light. Prior to administration the boxes containing the safety prefilled syringes with study treatment solution should be allowed to come to room temperature unopened for about [ADDRESS_99400] either secukinumab 
or placebo (blinded) via PFS following the IFU. After the Baseline Visit, the injections will be self-administered into the appropriate site of the body (thighs, arms, abdomen), and each 
injection should be given at a different injection site. Each new injection should be given at least one inch from the previously used site. If subject chooses the abdomen, [ADDRESS_99401], continued assistance by [CONTACT_90193].  
5.5.5 Permitted dose adjustments and interruptions of study treatment  
Study treatment dose adjustments are not permitted.  Study treatment interruptions are not permitted with the following exceptions:  
• If, in the opi[INVESTIGATOR_871], a subject is deemed to be placed at a significant safety 
risk unless dosing is temporarily interrupted. In such cases study treatment should be interrupt ed only during the time that this risk is present and ongoing. Study treatment can 
be restarted at the next scheduled visit after resolution of the safety risk.  
• The effect of secukinumab on live vaccines is unknown; therefore live vaccines should not be administered during participation in the study. In case a live vaccine has been administered due to a medical urgency, the subject  must  be discontinu ed from study 
treatment as per Section 5.6.2. Non -live vaccinations are permitted during the study.  
[COMPANY_001]  Confidential  Page 38  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Study treatment interruptions must be recorded on the corresponding Dos age Administration 
Record eCRF page and all assessments should be completed as scheduled.   
5.5.6 Rescue medication 
Rescue medication is not permitted during the study. Patients will be free to discontinue 
participation in the study at any time.  
5.5.7 Concomitant medication 
Patients should be instructed to notify the study site about any new medications he/she takes after being enrolled into the study. All medications, procedures and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy and blood transfusions) administered after the patien t was 
enrolled into the study must be recorded in the appropriate eCRF. 
Guidelines for the use of specific medications are provided below: 
Methotrexate (MTX)  
Patients taking MTX (up to 25 mg/week) must be on a stable dose for at least [ADDRESS_99402] be taking folic acid supplementation before the Baseline Visit and during the study to minimize the likelihood of MTX associated toxicity. 
Sulfasalazine 
Subjects taking sulfasalazine (≤ 3 g/day) must be on a stable dose for at least 4 weeks before 
the Baseline Visit  and maintained stable throughout the duration of the study.  
Leflunomide 
Subjects taking luflunomide (≤ 20 mg/day) must be on a stable dose for at least 4 weeks before 
the Baseline Visit  and maintained stable throughout the duration of the study. 
Low Strength opi[INVESTIGATOR_90158]. However, patients should not take a 
dose of low strength opi[INVESTIGATOR_39863] 24 hours of a study visit. High potency opi[INVESTIGATOR_2467] 
(e.g., methadone, hydromorphone, morphine) are prohibited in this study.  
Systemic corticosteroids 
Treatment with systemic corticosteroids is permitted up to a maximum daily dosage of [ADDRESS_99403] should remain on a stable dose throughout the duration of the study. 
Higher- dose, time -limited corticosteroid courses (bursts) may be permitted for exacerbations of 
medical conditions unrelated to AS (e.g., asthma, chronic obstructive pulmonary disease 
(COPD), contact [CONTACT_8748]) after baseline. Any change in the dose of systemic corticosteroids 
during the trial must be recorded on the corresponding CRF. 
[COMPANY_001]  Confidential  Page 39  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Intra -articular corticosteroids are not permitted within the 4 weeks preceding the Baseline Visit 
and up to Week 52.  
Non-steroidal ant i-inflammatory drugs (NSAIDs) (including COX -1 or COX -2 
inhibitors) and acetaminophen 
Patients on regular use of NSAIDs or acetaminophen should be on stable dose for at least 2 
weeks before the Baseline Visit to allow inclusion in the study. They should remain on stable dose in the study up to Week 52.  
Subjects taking NSAIDs or acetaminophen PRN within the 2 weeks before baseline can 
continue to do so in the study; however, they have to refrain from any intake during the 24 hours before a visit .  
Any change of the NSAIDs or acetaminophen treatment during the trial should be recorded on 
the corresponding eCRF page 

[COMPANY_001]  Confidential  Page 40  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
5.5.[ADDRESS_99404] often, study treatment discontinuation and knowledge of 
the possible treatment assignments are sufficient to treat a study patient who presents wit h an 
emergency condition. Emergency treatment code breaks are performed using the IRT system. When the Investigator contacts the IRT system to break a treatment code for a patient, he/she must provide the requested patient identifying information and confi rm the necessity to break 
the treatment code for the patient. The Investigator will then receive details of the investigational drug treatment for the specified patient and a confirmation via email and/or fax. The system will automatically inform the [COMPANY_001] monitor for the site and the Clinical Trial Lead (CTL) that the code has been broken. 
It is the Investigator’s responsibility to ensure that there is a procedure in place in case of an 
emergency. The Investigator will inform the patient how to contact [CONTACT_5657]/her backup in cases of emergency when he/she is unavailable. The Investigator will provide protocol number, study treatment name [CONTACT_90228], patient number, and instructions for contact[CONTACT_90194] (or any entity to which it has delegated responsibility for emergency code breaks) to the patient in case an emergency treatment code break is required at a time when the Investigator and backup are unavailable. 

[COMPANY_001]  Confidential  Page 41  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
5.[ADDRESS_99405] scheduled administration of therapy will be at Visit 18/Week 48. A subject’s study 
participation is completed once Visit 19/Week [ADDRESS_99406]’s completion or discontinuation of the study and the reason for 
discontinuation of the study will be recorded on the corresponding CRFs.  
In any case, the investigator or site staff must contact [CONTACT_90195]’s study completion (Week 52) and/or wit hdrawal from the trial.  
The study as a whole will be completed once all enrolled patients have completed the study per the protocol and the clinical database has been locked. Recruitment into the study will be terminated by [CONTACT_90196]. Patients who have been screened and have a screening visit recorded in the IRT system at the time that the planned enrollment number is met will be allowed to enter the trial and to be randomized if they are eligible.  
Upon completion of study participation, patients will return to individual medical treatment, as determined by [CONTACT_24018].  
The Investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care.  
5.6.[ADDRESS_99407] be discontinued from the trial altogether. 
The following circumstances require study treatment discontinuation and consequently 
discontinuation from the trial:  
• Withdrawal of informed consent  
• Emergence of the following adverse events: 
a. Any severe or serious adverse event that in the judgment of the investigator/ qualified 
site staff, taking into account the subject ’s overall status, prevent the subject  from 
continuing study treatment; 
b. Any laboratory abnormalities that in the judgment of the investigator are clinically 
significant and are deemed to place the subject at a safety risk for continuation in the study (A general guidance on clinically notable laboratory values is provided in 
. 

[COMPANY_001]  Confidential  Page 42  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
c. Life-threatening infection  
• Pregnancy; 
  
 
• Emergency unblinding  
• Patient refusal to complete PRO questionnaires at Baseline, Week 12 or Week 16  
• Any other protocol deviation that results in a significant risk to the subject’s safety;  
For any subject whose treatment code has been broken inadvertently for any reason, the 
appropriate personnel from the site and [COMPANY_001] will assess whether study treatment should be discontinued.  
The investigator must also contact  [CONTACT_90197]’s discontinuation from 
study treatment. Patients may voluntarily withdraw from the study for any reason at any time. They may be 
considered withdrawn if they state an intention to withdraw, fail to return for visits,  or become 
lost to follow -up for any other reason. 
5.6.[ADDRESS_99408] make every effort (e.g. 
telephone, e -mail, letter) to determine the primary reason for this decision and record this 
information in the patient source and on the appropriate study completion eCRF.  
Patients who withdraw consent should return for an End of Study Visit  (see Table 6 -1). The 
End of Study Visit should be scheduled approximately four weeks after the last study treatment, 
and should be performed before any new treatment is initiated. After the End of Study Visit, any SAEs that occur in the followin g [ADDRESS_99409] to follow -up (i.e., those patients whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), the investigator should 
show "due diligence" by [CONTACT_762], e.g. dates of telephone calls, registered letters, etc. 

[COMPANY_001]  Confidential  Page 43  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
5.6.5 Early study termination by [CONTACT_90198] s at any time for any reason. This may include reasons 
related to the benefit risk assessment of participating in the study, practical reasons, or for 
regulatory or medical reasons (including slow enrollment). Should this be necessary, the subject should be seen as soon as possible and treated as a prematurely withdrawn as described in Section 5.6.2. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subject’s interests. The investigator will be responsible for informing Institutional Review Board/Independent Ethics Committee (IRBs/ECs) of the early termination of the trial.  
6 Visit schedule and assessments 
Table 6 -1 lists all of the assessments and indicates with an “X ” when the visits are performed. 
Assessments that will only be reported in the source documentation are marked with an ‘S ’. 
Patients/subjects must be seen for all visits on the designated day, or as close to it as possible. Missed or rescheduled visits should not lead to automatic discontinuation. For patients unable to travel to the clinic for their study visit, flexible study  visits (home nursing study visits) and 
telemedicine/telephone visits with direct to patient shipment of study drug are alternative options for all post -Baseline study visits.   For more information regarding flexible study visits, 
please refer to the Site Manual for Home Visits (Flexible Study Visits). Patients who 
prematurely discontinue the study for any reason should be scheduled for an End of Study Visit as soon as possible, at which time all of the assessments listed will be performed. At this End of St udy Visit, all dispensed investigational product should be reconciled and the adverse event 
and concomitant medications reconciled on the CRF. 
If patients do not have a chest X -ray available within [ADDRESS_99410] meets inclusion/exclusion criteria in order to 
minimize unnecessary exposure to radiation.  
Patients evaluated at Screening Visit 1 and 2 for Inclusion/Exclusion criteria should not be 
screen failed on the basis of a medicat ion requiring washout, unless the subject will be unable 
to complete the washout in the appropriate time frame before the Baseline Visit.  
Screening will be flexible in duration based on the time required to be evaluated for eligibility. Sufficient time is allowed for potential medication washout, in addition to all other assessments indicated in Table [ADDRESS_99411] of two consecutive visits. During Screening Visit 1 (SV1)  and Screening 
Visit 2 (SV2), initial assessments will be performed as outlined in Table [ADDRESS_99412] one week in between these two screening visits.    

[COMPANY_001]  Confidential  Page 44  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
Premature Discontinuation 
For patients  who discontinue study tr eatm ent prematurely for any re ason after baseline, an 
End of Study Visit must be  perf ormed  approx imate ly four weeks after the last dose of study 
treatment .  In accordance with SAE reporting guidelines, a ny SAEs reported in the [ADDRESS_99413] should be recorded in the source 
documentation. 
Unscheduled visits  
Patients may be seen at any time for an unscheduled visit , e.g., if they experience deterioration 
or AEs that in the opin ion of the investigator/qualified site staff need intervention or repeat 
laboratory testing. The assessment(s) performed at an unscheduled visit must include at minimum: an assessment of concomitant medication and procedures/significant non-drug therapi[INVESTIGATOR_014],  vital signs, and an AE/SAE assessment. Any additional assessments performed are at 
the investigator/qualified site staff’s discretion. During an unscheduled visit, study treatment will not be administered.  
[COMPANY_001]  Confidential  Page 45  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Table 6-1 Assessment schedule 
 
Period SCR1 Treatment Period 1  
(Open -Label)  Treatment Period 2  
 (Double -Blind or Open -Label)     
Week  -13 
to 
-3 -2 
to 
BL BL 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48 52/Study 
Completion/  
EOS2 Telemedicine/
telephone 
visit Unscheduled Notes  
Visit No  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19    
Assessments                        
Obtain 
informed 
consent  X                     
See section 
10.2 
Inclusion / 
exclusion 
criteria  X X X                   
See sections  
4.1 – 4.2 
Demographics  X                     See section 
6.3 
General 
Medical history 
/ previous 
therapi[INVESTIGATOR_014]  X                     
See section 
6.3 
Relevant AS 
medical history 
/ current 
medical 
conditions  X                     
See section 
6.3 
Washout 
evaluation / 
instruction  S                     
See Table 5 -
1 
Modified NY 
criteria  S S S                   See section 
13.2 
Radiologic 
evidence (x -
ray) to central 
reader   X                    
See section 
6.6.9  
[COMPANY_001]  Confidential  Page 46  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Period SCR1 Treatment Period 1  
(Open -Label)  Treatment Period 2  
 (Double -Blind or Open -Label)     
Week  -13 
to  
-3 -2  
to 
BL BL 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48 52/Study 
Completion/  
EOS2 Telemedicine/
telephone  
visit Unscheduled Notes  
Visit No  [ADDRESS_99414] X -ray  X                    See section 
6.6.2  
ECG  X                    See section 
6.6.3  
Prior/ 
Concomitant 
medication/ 
non-drug 
therapy  X X X X X X X X X X X X X X X X X X X X X See section 
5.5.7  
[COMPANY_001]  Confidential  Page 47  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Period SCR1 Treatment Period 1  
(Open -Label)  Treatment Period 2  
 (Double -Blind or Open -Label)     
Week  -13 
to  
-3 -2 
to 
BL BL 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48 52/Study 
Completion/  
EOS2 Telemedicine/
telephone 
visit Unscheduled Notes  
Visit No  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19    
Assessments                        
IRT transaction  S S S S S S S S S S S S S S S S S S S X  See section 
5.3 
Administration 
of s.c. study 
treatment via 
PFS    X X X X X X X X X X X X X X X X  X  See section 
5.5.4  
Adverse 
Events/SAEs 
(inc. injection 
site reaction & 
occurrence of 
infections)  X X X X X X X X X X X X X X X X X X X X X See section   
7.1 – 7.[ADDRESS_99415]   X                    See section 
6.6.1  
Hematology, 
blood 
chemistry4  X X      X X   X   X   X   See section 
[IP_ADDRESS] -
[IP_ADDRESS]  
Serum 
pregnancy test   X                    See section 
6.6.8  
Urinalysis/Urin
e pregnancy 
test   X    X  X X  X  X  X   X   See section 
[IP_ADDRESS] and 
6.6.8  
HLA-B27  X                    See section 
[IP_ADDRESS]  

[COMPANY_001]  Confidential  Page 48  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Period SCR1 Treatment Period 1  
(Open -Label)  Treatment Period 2  
 (Double -Blind or Open -Label)     
Week  -13 
to  
-3 -2  
to 
BL BL 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48 52/Study 
Completion/  
EOS2 Telemedicine/
telephone 
visit Unscheduled Notes  
Visit No  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19    
Assessments                        
Responder 
status 
assessment           X          X  See section 
3.1 
BASDAI X5 X X X X X X X X X X X X X X X X X X X  See section 
[IP_ADDRESS]  
Patient’s global 
assessment of 
disease activity  X5 X X X X X X X X X X X X X X X X X X X  See section 
[IP_ADDRESS]  
ASAS- HI   X    X X X X X X X X X X X X X X  See section 
6.5.4  
FACIT -Fatigue 
v4   X X X X X X X X X X X X X X X X X X  See section 
6.5.6  

[COMPANY_001]  Confidential  Page 49  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Period SCR1 Treatment Period 1  
(Open -Label)  Treatment Period 2  
 (Double -Blind or Open -Label)     
Week  -13 
to  
-3 -2 
to 
BL BL 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48 52/Study 
Completion/  
EOS2 Telemedicine/
telephone 
visit Unscheduled Notes  
Visit No  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19    
Assessments                        
Treatment 
period 1 
completion 
form          X          X   
Treatment 
period 2 
completion 
form                   X X   
  
   
2 Patients who discontinue prematurely or withdraw consent should return for an End of Study Visit. The End of Study Visit should be scheduled approximately four (4) weeks after the last study  
treatment and should be performed before any new treatment is initiated.  
3 The Physical Exam is documented in the source; not in the database.  If flexible study visits are permitted, a limited physical assessment will be performed by [CONTACT_90199] a complete physical 
examination.  
4 Fasting sample  
5 Measures captured only for TNF inhibitor inadequate responders currently on a TNF inhibitor and prior to discontinuation/washout.  
 

[COMPANY_001] Confidential  Page 50  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
6.1 Rescreening  
Rescreening may be allowed under certain conditions.  Requests from the investigator/site staff 
to rescreen patients will be handled on a case -by-case basis with Medical Director approval 
required before proceeding with the rescreening.  Rescreening cannot be done if the patient 
previously entered Treatment Period [ADDRESS_99416] be performed per protocol, except the 
tuberculosis (TB) work up (if applicable).  If the date of the TB work up is less than 12 wee ks 
from the projected baseline date, then it is not required that the TB work up be repeated; however, the rescreened patient MUST repeat the QuantiFERON test performed by [CONTACT_2237]. 
6.[ADDRESS_99417] be notified about the discontinuation, and the primary reason for the screen failure should be entered in the Screen ing Phase Disposition 
eCRF.  
In addition, only the following eCRFs should be completed: Demography eCRF, Informed Consent eCRF, Inclusion/Exclusion eCRF, and the adverse event (AE) eCRF should be completed for any Serious Adverse Events (SAEs) that occurred during the Screening Period. Adverse events that are not serious will be followed by [CONTACT_90200].  
6.3 Patient demographics/other baseline characteristics  
At Screening Visit 1, subject demographic and baseline characteristic data to be collected on all subjects and to be recorded in the CRF include: 
• Age, sex, race, ethnicity  
• Relevant AS and general medical history/current medical condition data until the start of investigational treatment: date of AS symptom onset (specifically axial symptom onset in the back, buttock or hip pain), date of AS diagnosis, targeted medical history events related to AS, such as the history of extra- axial involvement (uveitis, psoriasis, 
inflammatory bowel disease, enthesitis, peripheral ar thritis), number of previous 
DMARDs used, previous AS therapi[INVESTIGATOR_014], functional status class according to [LOCATION_001] criteria, cardiovascular medical history and smoking history.  
Where possible, diagnoses and not symptoms will be recorded. 
[COMPANY_001] Confidential  Page 51  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Investigators will have the discretion to record abnormal test findings on the CRF capturing 
medical history whenever in their judgment the test abnormality occurred prior to the informed consent signature.  
6.4 Treatment exposure and compliance  
All dates and  times of study treatment administration will be recorded on the appropriate CRF. 
Drugs administered prior to start of treatment and other drugs/procedures continuing or started during the study treatment period will be entered in the appropriate CRF. 
Compliance is expected to be 100%, unless temporary interruption is needed for safety reasons 
as described in Section 5.5.5. Compliance will be assessed by a field monitor using
 information provided by [CONTACT_90201]. All study treatment 
dispensed and returned must be recorded in the Drug Accountability Log. 
6.5 Efficacy  
• Ankylosing Spondylitis Disease Activity Score (ASDAS) and ASDAS response categories  
• Assessment of Spondyloarthritis International Society criteria (ASAS)  
• Patient’s global assessment of disease activity  
• Patient’s assessment of back pain intensity  
  
• Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
  
• ASAS -Health Index (ASAS- HI) 
  
• FACIT - Fatigue 
All efficacy assessments should be performed prior to administration of study treatment. Details relating to the administration of all PROs are provided in Appendix 4. 
6.5.1 ASDAS and ASDAS response categories 
The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess 
disease activity in AS. The ASDAS -CRP (Ankylosing Spondylitis Disease Activity Score) will 
be utilized to assess the disease activity status. Param eters used for the ASDAS calculation 
include:  
1. Spi[INVESTIGATOR_18172] (BASDAI question 2),  
2. The patient’s global assessment of disease activity,  
3. Peripheral pain/swelling (BASDAI question 3),  
4. Duration of morning stiffness (BASDAI question 6) and  
5. C-reactive protein (CRP) in mg/L (Sieper 2009, Lukas 2009).  
Disease activity states are inactive disease, moderate disease activity, high disease activity, and very high disease activity. The 3 values selected to separate these states were:  

[COMPANY_001] Confidential  Page 52  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
• < 1.3 between inactive disease and moderate disease activity,  
• < 2.1 between moderate disease activity and high disease activity, and  
• 3.5 between high disease activity and very high disease activity.  
Selected cutoffs for improvement scores were a change ≥ 1.1 unit for “clinically important 
improvement” and a change ≥ 2.0 units for “major improvement” ( Machado 2011).  
6.5.2 Assessment of Spondylo- Arthritis International Society criteria (ASAS)  
The ASAS response measures consist of the following assessment domains ( Sieper 2009).  
ASAS domains: 
• Patient’s global assessment of disease activity measured on a NRS  
• Patient’s assessment of back pain, represented by [CONTACT_90202], 
both measured on a NRS  
• Function represented by [CONTACT_90203] 10 questions regarding ability to perform specific tasks as measured by a NRS  
• Inflammation represented by [CONTACT_90204], represented  by [CONTACT_90205] 2 questions on the 6- question BASDAI as 
measured by a NRS  
[IP_ADDRESS] ASAS Responder Criteria 20% (ASAS20)  
ASAS 20 response is defined as an improvement of ≥ 20% and ≥ [ADDRESS_99418] three of the four domains and no worsening of ≥ 20% and ≥ 1 unit on a scale of 10 in the remaining domain. Assessments will be made relative to patient’s baseline values.  
[IP_ADDRESS] ASAS Responder Criteria 40% (ASAS40)  
ASAS 40 response is defined as an improvement of ≥ 40% and ≥ [ADDRESS_99419] three of the four domains and no worsening at all in the remaining domain. Assessments will be made relative  to patient’s baseline values.  
[IP_ADDRESS] ASAS partial remission criteria  
The ASAS partial remission criteria are defined as a value not above 2 units in each of the four domains on a scale of 10. 
   
  
   

[COMPANY_001] Confidential  Page 53  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
   
 
     
 
  
      
 
6.
5.2.7 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
The BASDAI will be completed at Visits 2 – 19.  It consists of a 0 through 10 scale ([ADDRESS_99420] problem, captured using a NRS ), which is used to answer 6 
questions pertaining to the 5 major symptoms of AS: 
1. Fatigue 
2. Spi[INVESTIGATOR_18172] 
3. Joint pain / swelling  
4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments)  
5. Morning stiffness severity  
6. Morning stiffness duration 
To give each symptom equal weighting, the mean (average) of the two scores relating to 
morning stiffness is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 – [ADDRESS_99421] suboptimal control of disease, and subjects with scores of 4 or greater are usually good candidates for either a change in their medical therapy or for  enrollment in clinical 
studies evaluating new drug therapi[INVESTIGATOR_90159]. BASDAI is a quick and simple index taking between 30 seconds and 2 minutes to complete. Note: BASDAI is only assessed at 
Screening Visit 1 for TNF inhibitor inadequate responders  currently on a TNF inhibitor and 
prior to discontinuation/washout. 
 

[COMPANY_001] Confidential  Page 54  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
  
 
  
 
6.
5.4 ASAS Health Index (ASAS -HI) 
The ASAS- HI is administered at Visit 3 and Visits 7 – 19.  It is a self -administered questionnaire 
and measures functioning and health over 17 aspects of health and 9 environmental factors in patients with spondyloarthritis. Items include pain, maintaining a body position, moving 
around, toileting, energy/drive, motivation, sexual functions, driving, community life, handling stress, recreation/leisure, emotional functions, washing oneself, economic self -sufficiency, and 
sleep. Patients score each item as “I  agree” and “I do not agree”. 
  
           
  
6.5.6 Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-
Fatigue)  
The FACIT -Fatigue© is a 13- item questionn aire ( Cella 1993; Yellen 1997) that assesses self -
reported fatigue and its impact upon daily activities and function. It is administered at Visits 3 – 19. 
6.5.[ADDRESS_99422] of evaluating all AEs and SAEs including injection site reactions, ECGs, physical examination, vital signs and laboratory as sessments, and assessment 
of anti-secukinumab antibody development (immunogenicity). 

[COMPANY_001] Confidential  Page 55  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
All blood draws and safety assessments should be done prior to study treatment administration. 
Appropriate safety assessments (e.g. evaluation of AEs and SAEs including in jection site 
reactions) should be repeated after the dose is administered.  
• Determination of tuberculosis status  
• Chest X -ray 
• Electrocardiogram  
• Physical examination  
• Vital signs  
• Height and weight  
• Laboratory evaluations (Hematology, Clinical Chemistry, LFTs, Urinalysis)  
• Pregnancy and assessment of fertility  
• Tolerability of secukinumab  
• Local tolerability (Injection site reactions)  
• Evaluation of AE/ SAE’s  
All blood draws and safety assessments should be done prior to study treatment administration. Appropriate safety assessments (e.g., evaluation of AEs and SAEs including injection site reactions) should be repeated after the dose is administered.  
6.6.1 Determination of tuberculosis status  
Determination of tuberculosis (TB) status will be required before administratio n of study 
treatment. TB status must be determined by [CONTACT_9870], signs, symptoms, and TB testing (QuantiFERON- TB Gold assay). If the QuantiFERON -TB Gold Assay test is positive or 
indeterminate, a TB workup should be performed as defined by [CONTACT_90206]’s TB status.  
QuantiFERON TB- Gold In -Tube assay  
A QuantiFERON
® TB-Gold In- Tube assay will be performed to assess the TB status at 
screening for all patients. This test will only be used to determine subject’s eligibility for the trial. The test will be used to screen the subject population for latent tuberculosis infection (Doherty et al 2008).  
This blood -based assay is specific for Mycobacterium tuberculosis and is not influenced by 
[CONTACT_37257] -Guérin vaccination or exposure to other Mycobacteria species.  
This test, in contrast to the purified protein derivative ([COMPANY_003]) skin test, is also insensitive to a booster effect since the subject is not exposed to the vaccine. The assay measures the production 
of interferon -gamma and presents it relative to a negative and a positive control sample ( Manuel 
and Kumar 2008)  
The QuantiFERON® -TB Gold assay test will be supplied by [CONTACT_2237]. Details on 
the collection, shipment of samples and reporting of results by [CONTACT_90207]. 
The results of a TB workup for a subject with a positive or indeterminate test must be recorded 
in the eCRF . 
[COMPANY_001] Confidential  Page 56  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
• If the test result is negative , the subject may be randomized. 
• If the test result is positive , the investigator should perform a TB workup for the test result 
as per local procedures.  
• Patients positive for latent TB per workup may be randomized to the tr ial if sufficient 
treatment has been initiated according to local routine clinical practice and will be 
maintained for the prescribed duration. 
• Patients positive for active TB per workup are not eligible for the study. 
• Patients negative for TB (no signs of latent or active TB) per workup may be randomized to the trial.   
• If the test result is indeterminate , it is recommended to repeat the test once. The 
investigator may decide to skip the repetition of the test and proceed directly to the workup (however this is not recommended). If a TB workup was conducted prior to screening, results from the workup can be used to assess eligibility if the workup was conducted within 12 weeks prior to baseline. 
• If the second test is negative, the subject may be randomized. 
• If the second test is positive or indeterminate , the investigator should perform a TB 
workup as per local guidelines. The subject will not be eligible for randomization if: “active tuberculosis is present”, or if “latent tuberculosis is present” and is untreated as per local guidelines.  
6.6.[ADDRESS_99423] meets the other inclusion/exclusion criteria in order to minimize unnecessary exposure to X- ray radiation for patients.  
If the chest X -ray, CT scan, or MRI evaluated by a qualified physician shows evidence of 
ongoing infection or malignancy and the subject was not treated subsequent to the X -ray (CT 
scan or MRI), the subject will not be eligible to enter the study.  
6.6.3 Electrocardiogram (ECG)  
A standard [ADDRESS_99424] number, date and time, and filed in the study site source documents. 
Clinically relevant abnormalities should be recorded on the relevant medical history/Current 
medical conditions eCRF page for the baseline ECG.  
Clinically relevant abnormalities noted after the baseline ECG should be reported as AE (see 
Section 7 ). 
[COMPANY_001] Confidential  Page 57  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
6.6.[ADDRESS_99425] of a complete physical examination.  For more information regarding 
flexible study visits, please refer to the Site Manual for Home Visits (Flexible Study Visits).  
Information for all physical examinations must be included in the source documentation at the study site. Significant findings that are present before signing the ICF must be included in the relevant medical history eCRF. Significant findings made after signing the ICF which meet the definition of an AE must be recorded in the Adverse Event eCRF. 
6.6.5 Vital signs  
Vital signs will be assessed at Visits 2 – [ADDRESS_99426] has been sittin g for five minutes, with back supported and both 
feet placed on the floor, systolic and diastolic blood pressure will be measured using a validated 
device with an appropriately sized cuff. 
If possible, vital signs assessments should be performed by [CONTACT_90208]. 
Clinically notable vital signs are defined in   
6.6.6 Height and weight  
Height (without shoes) will be measured at S creening Visit 2.  Body weight (in indoor clothing 
but without shoes) will be measured at Screening Visit 2 and Visits 3, 10 and 19. If possible, 
body weight assessments should be performed using the same scale throughout the study. The Body Mass Index wil l be calculated by [CONTACT_1624].  
6.6.7 Laboratory evaluations  
A central laboratory will be used for analysis of all specimens collected listed below (except urinalysis). Details on the collection, shipment of samples and reporting of results by [CONTACT_90209]. For the identification of clinically notable 
values, see  All patients with laboratory tests containing clinically significant 
abnormal values are to be followed until the values return to normal ranges or until a valid reason, other than treatment related AE, is defined.  
[IP_ADDRESS] Hematology  
Hemoglobin, platelet, red blood cell (RBC), white blood cell (WBC) and differential white blood cell counts will be measured at Screening Visit 2, and Visits 3, 9, 10, 13, 16 and 19. 

[COMPANY_001] Confidential  Page 58  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
[IP_ADDRESS] Clinical chemistry  
Measured at Screening Visit 2, and Visits 3, 9, 10, 13, [ADDRESS_99427] (SGOT), ALT (SGPT), GGT , alkaline 
phosphatase, sodium, potassium, bicarbonate, calcium, phosphorous, total protein, albumin, and uric acid.  
[IP_ADDRESS] Urinalysis  
Urinalysis will be performed at Visits 3, 7, 9, 10, 12, 14, [ADDRESS_99428] parameters such as protein, glucose, blood and WBCs will be recorded in the appropriate eCRF page.  
[IP_ADDRESS] HLA-B27 
HLA- B27 will be performed at Screening Visit 2.  
6.6.[ADDRESS_99429] not be given to pregnant women; therefore effective methods of birth control must be used for women of child -bearing potential (see exclusion criteria definitions,  Secti on 
4.2). 
A serum β- hCG test will be performed in all women of child bearing potential at Screening 
Visit 2; and a local urine pregnancy test at Visits 3, 7, 9, 10, 12, 14, [ADDRESS_99430] -baseline, the 
x-ray should be sent to the central reader immediately.  
Investigator sites will receive training on the submission process from the central reader.  Once 
training is completed, sites will be expected to implement this requirement.  
6.6.10 Tolerability of secukinumab 
Tolerability will be assessed by [CONTACT_20721], laboratory values and injection site reaction.  
6.6.11 Local tolerability  
The local tolerability at the site of s.c. injection of the study treatment will be assessed in case 
of any local reaction, until this has disappeared.  
The assessment of pain, redness, swelling, induration, hemorrhage and itching will be performed by a physician and will be recorded on the appropriate CRF capturing AEs, including the severity (mild, moderate, severe) and the duration of the a dverse reaction.  
[COMPANY_001] Confidential  Page 59  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
6.6.[ADDRESS_99431] and adequate for this indication/subject population. A chest X -ray at screening (or within 3 months prior to screening) is performed to 
rule out the presence of a pulmonary malignancy or infectious process, in particular tuberculosis. The radiation exposure that results from th e chest X -ray safety measurements are 
estimated to be far below 1 mS. Effective radiation doses under 3 mS (300 mrem), are considered to be minimal risk. Therefore, the radiation exposure in this study involves minimal risk and is necessary to ensure reliable safety measures before the treatment with a biologic.  
  
  
 
  
 
    
 
  
 
 
 
  
     
  
     
 
  
 
  
 
  
 

[COMPANY_001] Confidential  Page 60  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
  
 
  
 
  
  
 
  
 
 
   
   
   
   
   
   
   
   
    
 
  
       
 

[COMPANY_001] Confidential  Page 61  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
7 Safety Monitoring  
7.1 Adverse events  
An adverse event (AE) is any untoward medical occurrence (i.e., any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent  for participation in the 
study. Therefore, an AE may or may not be temporally or causally a ssociated with the use of a 
medicinal (investigational) product.  
In addition, all reports of intentional misuse and abuse of the product are also considered an adverse event irrespective if a clinical event has occurred.  
The occurrence of adverse events sh ould be sought by [CONTACT_105] -directive questioning of the patient 
at each visit during the study. Adverse events also may be detected when they are volunteered by [CONTACT_24479], laboratory test, or other assessments.  
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least one of the following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results should be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_90160]. Investigators have the responsibility for managing the safety of individual patient and identifying adverse events.  
 
Adverse events should be recorded in the Adverse Events CRF under the signs, symptoms or diagnosis associated with them, accompanied by [CONTACT_6644]. 
• the severity grade  
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
• relationship to the  study treatment (no/yes)  
• duration (start and end dates) or if the event is ongo ing an outcome of not recovered/not 
resolved should be reported. 
• whether it constitutes a serious adverse event  
 
• action taken regarding study treatment  
• All a dverse events should be treated appropriately. Treatment may include one or more of 
the following:  
• no action taken (i.e. further observation only)  

[COMPANY_001] Confidential  Page 62  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
• study treatment temporarily interrupted  
• study treatment permanently discontinued due to this adverse event  
• concomitant medication given  
• non-drug therapy given  
• patient hospi[INVESTIGATOR_057]/patient’s hospi[INVESTIGATOR_18533]  
• outcome (not recovered/not resolved; recovered/resolved; recovered/resolved with 
sequelae; fatal or unknown) 
Once an adverse event is detected , it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome.  
Information about common side effects already known about the investigational drug can be found in the Investigator Brochure (IB) or will be communicated between IB updates in the form of Investigator Notifications. This information will be included in the patient informed consent and should be discussed with the patient during the study as needed. 
The investigator should also instruct each patient to report any new adverse event (beyond the 
protocol observation period) that the patient, or the patient’s personal physician, believes might 
reasonably be related to study treatment. This information should be recorded in the investigator’s source documents. However, if the AE meets the criteria of an SAE,  it must be 
reported to [COMPANY_001].  
7.2 Serious Adverse Events  
7.2.1 Definition of SAE  
An SAE is defined as any adverse event (appearance of (or worsening of any pre -existing) 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the followin g 
criteria:  
• is fatal or life -threatening  
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition (specify what this includes)  
• elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]  
• social reasons and respi[INVESTIGATOR_064]’s general condition 
[COMPANY_001] Confidential  Page 63  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
• is medically significant, i.e. defined as an event that jeopardizes the patient or may 
require medical or surgical intervention.  
All malignant neoplasms will be assessed as seriou s under “medically significant” if other 
seriousness criteria are not met.  
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetica lly might have 
caused death if more severe (see Annex IV, ICH -E2D Guideline). 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_76593]. Examples of such events are intensive treatment in an emergency room or a t home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_6536] (see Annex IV, ICH-E2D Guideline). 
Any suspected transmission via a medicinal product of an infectious agent is al so considered a 
serious adverse reaction.  
All AEs (serious and non- serious) are captured on the CRF, SAEs also require individual 
reporting to [COMPANY_001] DS&E as per Section [IP_ADDRESS]. 
[IP_ADDRESS] SAE Reporting  
To ensure patient safety, every SAE, regardless of causality, occurring after the patient has 
provided informed consent and until [ADDRESS_99432] be reported separately as a new event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report Form; all applicable sections of the form must be completed in order to provide a clinically thorough report. The investigator must assess the relationship of each SAE to each specific 
component of study treatment, (if study treatment consists of several components) complete the SAE Report Form in English, and submit the completed form within [ADDRESS_99433] be reported as a follow -up to that event 
regardless of when it occurs. The follow-up information should describe whether the event has 
[COMPANY_001] Confidential  Page 64  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
resolved or continues, if and how it was treated, whether  the blind was broken or not, and 
whether the patient continued or withdrew from study participation.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study treatment a Drug Safety and Epi[INVESTIGATOR_90161]. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all investigators involved in any study with the same study treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/[ADDRESS_99434] of blocking IL -17A on the kidney. All subjects with laboratory tests 
containing clinically significant abnormal values (see  for notable laboratory values) 
are to be followed until the values return to normal ranges or until a valid reason, other than treatment related AE, is defined. Standard renal function tests (blood urea nitrogen, serum creatinine) will be obtained at regular intervals, but special measures for renal safety monitoring are not planned. 
7.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the contro l of a healthcare professional, subject or 
consumer (EMA definition).  
Misuse refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the protocol. 
Abuse corresponds to the persistent or sporadic, i ntentional excessive use of a medicinal 
product, which is accompanied by [CONTACT_3584]. Study treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the appropriate dose medication CRF irrespe ctive of whether or not associated with an AE/SAE 
and reported to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective of it being associated with an AE/SAE.  

[COMPANY_001] Confidential  Page 65  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Table 7-1 Guidance for capturing the study treatment errors including misuse 
Treatment error 
type Document in Dose Administration (DAR) 
eCRF (Yes/No)  Document in AE eCRF  Complete SAE form 
Unintentional study 
treatment error  Yes Only if associated 
with an AE  Only if associated 
with an SAE  
Misuse/Abuse Yes Yes Yes, even if not associated with 
an SAE  
7.[ADDRESS_99435] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abn ormalities, or maternal 
and/or newborn complications. 
Pregnancy should be recorded on the Pharmacovigilance Pregnancy Form and reported by [CONTACT_90210][INVESTIGATOR_066]. Pregnancy follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the study treatment.  
Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported on a SAE form. 
8 Data review and database management 
8.1 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] representative will review the protocol and CRFs with the investigators and their staff. During the study, [COMPANY_001] employs several methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness 
of patient records, the accuracy of entries on the (e)CRFs, the adherence to the protocol and to 
Good Clinical Pra ctice, the progress of enrollment, and to ensure that study treatment is being 
stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits.   
The investigator must maintain source documents for each patient in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the 
[COMPANY_001] Confidential  Page 66  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
patient's file. The investigator must also keep the original informed consent form signed by [CONTACT_4677] (a signed copy is given to the patient). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the CRF entries. [COMPANY_001] monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of 
SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study- specific 
monitoring plan. No information in source documents about the identity of the patients will be disclosed. 
8.[ADDRESS_99436] the data. Randomization codes and data about all study drug(s) assigned to the subject will be tracked using an Interactive Response Technology (IR T). The system will be supplied 
by a vendor, who will also manage the IRT database. The database will be sent electronically to [COMPANY_001] (or a designated CRO). Each occurrence of a code break via IRT will be reported to the clinical team and study monitor.  The code break functionality will remain available until study completion or upon request of [COMPANY_001]. 
Concomitant medications entered into the database will be coded using the WHO Drug 
Reference List, which employs the Anatomical Therapeutic Chemical classification system. Concomitant procedures, non- drug therapi[INVESTIGATOR_90162] (MedDRA) terminology.  
Laboratory samples will be processed centrally and the results will be sent electr onically to a 
designated CRO.  
The occurrence of relevant protocol deviations will be determined. After these actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unbli nded and made available for data analysis. Any 
[COMPANY_001] Confidential  Page 67  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
changes to the database after that time can only be made after written agreement by [CONTACT_90211]. 
8.4 Data monitoring committee  
Not required. 
8.5 Adjudication committee  
Not required. 
9 Data analysis  
It is planned  that the data from all centers that participate in this protocol will be combined, so 
that an adequate number of patients will be available for analysis.  
The analysis will be conducted on all patient data at the time the trial ends.  
Any data analysis car ried out independently by [CONTACT_85689]. Upon completion of Treatment Period 1 (Week 16), responders will enter Treatment Period 2 
and continue to receive secukinumab 150mg every 4 weeks through Week 48. Inadequate responders will enter Treatment Period 2 and will be randomized (1:1, double- blinded) to 
secukinumab 300 mg or secukinumab 150 mg very 4 weeks through Week 48. Nonresponders will be discontinued from the study at Week 16. 
Effic acy, safety, and other data from Treatment Period 1, randomized Treatment Period 2 for 
inadequate responders, and blinded Treatment Period 2 for responders will be summarized.  For 
continuous variables, summary statistics (mean, standard deviation, median,  25th and 75th 
percentiles, interquartile range, minimum, and maximum) at each time point and for change 
from baseline to Week 16, and change from Week 16 to each time point by [CONTACT_90212].  For discrete variables, frequency counts and percentages at each time point 
will be reported by [CONTACT_1570]. 
9.1 Analysis sets  
The following analysis sets will be used for the statistical reporting and analyses:  
Enrolled Set:  The Enrolled Set consists of all enrolled patients for the initial 16-week, 
Treatment Period 1.  
Responder Set: The Responder Set consists of all patients who are labeled as responders at the end of Treatment Period 1, and enter Treatment Period 2 receiving blinded secukinumab 150 
mg every 4 weeks through Week 48. 
Randomiz ed Set: The Randomized Set consists of all randomized patients.   
Safety Set: The Safety Set includes all patients who received at least one dose of study treatment 
during Treatment Period 2.  Patients will be analyzed according to the study treatment rece ived. 
[COMPANY_001] Confidential  Page 68  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Full Analysis Set:  The Full Analysis Set comprises all patients to whom study treatment has 
been assigned by [CONTACT_17628].  Patients inappropriately randomized (e.g., IRT was called in error for randomization of a screen failed patient) will be excluded from this analysis set.  According to the intent -to-treat principle, patients will be analyzed according to the treatment 
they have been assigned to during the randomization procedure. 
9.2 Patient demographics and other baseline characteristics  
Demographic and other baseline data, including disease characteristics, will be listed and summarized descriptively for the Enrolled Set, for the Responder Set, and by [CONTACT_90213].  
Relevant medical histories and current medical conditions at baseline will be summarized by [CONTACT_6657], for the Enrolled Set, for the Responder Set, and by [CONTACT_90214].  
9.3 Treatments  
The duration of exposure (in days) will be summarized by [CONTACT_90215], for the Responder Set, and for each treatment group for the Safety Set. 
Concomitant medications and significant non- drug therapi[INVESTIGATOR_90163] (ATC) classification system, for the Enrolled Set, for the Responder Set, and by 
[CONTACT_90214].  
 
9.4 Analysis of the primary variable(s)  
9.4.1 Primary variable(s)  
The primary efficacy variable is the ASDAS inactive disease response (yes, no).  The primary analysis time point is at Week 52.  
9.4.2 Statistical model, hypothesis, and method of analysis 
Let π
j denote the probability of an ASDAS inactive disease at Week 52 for treatment group j, j 
= 1, 2, where 1 and 2 correspond to secukinumab 150 mg and secukinumab 300 mg, respectively.  Accordingly, π
j/(1 – π j) is the odds for treatment group j, j = 1, 2. 
The primary efficacy variable will be analyzed at each time point using a logistic regression model w ith treatment, TNF -alpha inhibitor status (naive, inadequate responder), and baseline 
body weight as explanatory variables ( Stokes, Davis, and Koch, 2012).  The odds ratios and 
95% confidence intervals for the odds ratios will be reported, based on the fitted model.  
The primary analysis of the primary efficacy variable will be based on the Full Analysis Set.  
9.4.3 Handling of missing values/censoring/discontinuations 
Post-randomization patients who discontinue prematurely for any reason will be considered 
non-responders from the time they discontinued.   
[COMPANY_001] Confidential  Page 69  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
In an additional analysis, missing data for ASDAS inactive disease response will be imputed 
using multiple imputation.  
9.4.4 Sensitivity analyses  
A 95% confidence interval for the difference between the two treatment groups in the proportion of patients who have ASDAS inactive disease will be calculated using the normal approximation to the binomial distribution for the Full Analysis Set.  
9.5 Analysis of secondary variables  
9.5.1 Efficacy variables 
The secondary efficacy variables are the following:  
1. Reduction in ASDAS ≥  1.1 from Week 16 (yes, no) 
2. Change from Week 16 in total BASDAI 
3. BASDAI50 response (yes, no)  
4. ASAS20 response (yes, no)  
5. ASAS40 response (yes, no)  
6. ASAS partial remis sion (yes, no) 
7. Change from Week 16 in ASAS- Health Index  
8. Change from Week 16 in FACIT-Fatigue 
Analyses of secondary efficacy variables 1 and 3 – 6 at each time point will be similar to the 
primary and sensitivity analyses of the primary efficacy variable.   
Secondary efficacy variables 2, 7, and 8 will be analyzed at each time point by [CONTACT_90170], Week 16 value, TNF-alpha inhibitor status (naive, inadequate responder), and baseline body weight as explanatory variables.  The least squares means of the treatment groups, least squares mean difference, and 95% confidence interval for the difference will be reported, based on the fitted linear model.  Missing data will be imputed using the last -observation- carried -forward method .  In an additional analysis, missing data 
will be imputed using multiple imputation.  
Analyses of the secondary efficacy variables will be based on the Full Analysis Set.  
9.5.2 Safety variables 
For safety analyses, the Enrolled Set will be used for Treatment Pe riod 1, and the Safety Set 
will be used for Treatment Period 2. All listings and tables will be presented for Treatment 
Period 1, for responders who enter Treatment Period 2, and by [CONTACT_90216]. 
Adverse even ts 
All information obtained on adverse events will be displayed by [CONTACT_90217]. The number (and percentage) of patients with adverse events will be summarized in the 
following ways: 
[COMPANY_001] Confidential  Page 70  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
by [CONTACT_3148], primary system organ class and preferred ter m; 
by [CONTACT_3148], primary system organ class, preferred term and maximum severity;  
by [CONTACT_3148], Standardized MedDRA Query (SMQ) and preferred term.  
Separate summaries will be provided for study medication related adverse events, death, 
serious adverse even ts, and other significant adverse events leading to discontinuation. 
A patient with multiple adverse events within a primary system organ class is only counted once towards the total of the primary system organ class.  
Vital signs  
All vital signs data will be listed by [CONTACT_1570], patient, and visit/time, and if ranges are available, abnormalities will be flagged. Summary statistics will be provided by [CONTACT_10659]/time.  
12-lead ECG  
All ECG data will be listed by [CONTACT_1570], patient and  visit/time; abnormalities will be 
flagged. Summary statistics will be provided by [CONTACT_10659]/time.  
Clinical laboratory evaluations  
All laboratory data will be listed by [CONTACT_1570], patient, and visit/time, and if reference ranges are availab le, abnormalities will be flagged. Summary statistics will be provided by 
[CONTACT_10659]/time.  
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
  
  
  
   

[COMPANY_001] Confidential  Page 71  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
 
  
 
 
 
 
 
  
 
9.7 Interim analyses  
No interim analysis is planned. 
9.8 Sample size calculation  
The sample size was calculated based on the primary efficacy variable (i.e., ASDAS inactive 
disease response) at Week 52 for the Full Analysis Set.  The expected ASDAS inactive disease 
response rates for secukinumab 300 mg and 150 mg treatment groups at Week 52 are 20% and 10%, respectively (corresponding to an odds ratio of 2.25), partly based on results from AIN457 F2310 (MEASURE 2) study.   With approximately 97 patients in each treatment group 
(total of 194 randomized patients), one will be able to estimate the difference between ASDAS inactive disease response rates of the two treatment groups at Week 52 with a “margin of error” (half -width of confidence interval) of 10% (corresponding to a standard error of 5%) for a two -
sided 95% confidence interval (Julious and Patterson, 2004; nQuery Advisor 7.0). 
It is expected that the study will need to enroll approximately 270 patients for the 16- week 
open- label period, to randomize approximately 194 patients who do not achieve ASDAS 
inactive disease status at Week 16 (inadequate responders).   This assumes that 10% of the 270 
enrolled patients will discontinue during the 16 -week open- label period; among the remaining 
enrolled patients, it is assumed that approximately 10% will be responders, 80% will be 
inadequate responders, and 10% will be non- responders.  
10 Ethical considerations 
10.1 Regulatory and ethical compliance  
This clinical  study was designed and shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese Ministry o f 
Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.  

[COMPANY_001] Confidential  Page 72  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
10.2 Informed consent process  
Eligible patients may only be included in the study after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative(s) of the patient. In cases where the patient’s representative gives consent, the patient should be informed about the study to the extent possible given his/her understanding. If the patient is capable of doing so, he/she should indicate assent by [CONTACT_90218] a separate assent form. Informed consent must be obtained before conducting any study- specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the patient source documents.  
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_90219]/IEC and a copy of the approved version must be provided to the [COMPANY_001] monitor after IRB/IEC approval.  
 
 
Women of child bearing potential should be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the contraception requirement for the duration of the study. If there is any question that the patient will not reliably comply, they should not be entered in the study. 
10.3 Responsibilities of the investigator and IRB/IEC  
Before initiating a trial, the investigator/institution should obtain approval/favorable opi[INVESTIGATOR_30757]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures (e.g., advertisements) and any other written information to be provided to patients. Prior to 
study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs, and regulatory authorities a s required. If an inspection of the clinical site 
is requested by a regulatory authority, the investigator must inform [COMPANY_001] immediately that this request has been made.  
10.4 Publication of study protocol and results  
[COMPANY_001] assures that the key design elem ents of this protocol will be posted in a publicly 
accessible database such as clinicaltrials.gov. In addition, upon study completion and finalization of the study report the results of this trial will be either submitted for publication and/or posted in a publicly accessible database of clinical trial results.  

[COMPANY_001] Confidential  Page 73  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
10.[ADDRESS_99437] Quality Management (QM) system that includes all activities 
involved in quality assurance and quality control, including the assignme nt of roles and 
responsibilities, the reporting of results, and the documentation of actions and escalation of issues identified during the review of quality metrics, incidents, audits and inspections. 
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_90220] (CQA), a group independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal standard operating procedures, and are performed according to written [COMPANY_001] processes.  
[ADDRESS_99438] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC and health authorities, where required, it cannot be implemented. All significant protocol deviations will be recorded and reported in the CSR.  
11.[ADDRESS_99439] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to implementation. Only amendments that are intended to eliminate an apparent immediate hazard to patients may be implemented immediately provided the Health Authorities are subsequently notified by [CONTACT_6670]/IEC is notified. Notwithstanding the need for approval of formal protocol amendments, the in vestigator is expected to take any 
immediate action required for the safety of any patient included in this study, even if this action represents a deviation from the protocol. In such cases, the reporting requirements identified in Section 7 Safety Monitoring should be followed. 
   
[COMPANY_001] Confidential  Page 74  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
[ADDRESS_99440].  
Baeten D, Sieper J, Braun J, et al (2015) Secukinumab, an interleukin-IL17A inhibitor, in 
ankylosing spondylitis. N Eng J Med; 373:2534-48. 
Baraliakos X, Landewe R, Hermann K -G, et al (2005) Inflammation in ankylosing 
spondylitis: a systematic description of the extent and frequency of acute spi[INVESTIGATOR_90164]. Ann Rheum Dis; 64:730-34. 
Baraliakos X, Listing J, Fr itz C, et al (2011) Persistent clinical efficacy and safety of 
infliximab in ankylosing spondylitis after 8 years --early clinical response predicts long -term 
outcome. Rheumatology; 50:1690-9. Batmaz, Ibrahim, et al. "Sleep quality and associated factors in  ankylosing spondylitis: 
relationship with disease parameters, psychological status and quality of life." Rheumatology 
international 33.4 (2013): 1039-1045. 
Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu 
S, Richards HB (2017) Effect of secukinumab on clinical and radiologic outcomes in ankylosing spondylitis: 2-year results from the randomized phase III MEASURE 1 study. Ann Rheum Dis; 76:1070-1077. 
Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein K, Morin C. 
(2012) The consensus sleep diary: standardizing prospective sleep self-monitoring. SLEEP;35(2):287 -302.Cella DF, Tulsky DS, Gray G, et al. (1993) The Functional Assessment 
of Cancer Therapy (FACT) scale: Development and validation of the general measure. Journal of Clinical Oncology; 11(3):570-9. 
Chen KY, Bassett DR (2005) The technology of accelerometry- based activity monitors: 
current and future. Med Sci Sports Exerc; 37([ADDRESS_99441]):S490-500 
Cosentyx [package insert] (2016) East Hanover NJ : [COMPANY_001].  
Deodhar, Atul, Jürgen Braun, Robert D. Inman, Michael Mack, Shreekant Parasuraman, 
Jacqueline Buchanan, Benjamin Hsu, Tim Gathany, and Désirée Van Der Heijde. "Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results 
from a randomized, placebo ‐controlled trial." Arthritis care & research 62, no. 9 (2010): 1266-
1271. 
Doherty SD, Van Voohes A, Lebwohl MG (2008) National Psoriasis Foundation consensus 
statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol; 59(2):209-17. 
Gladman DD (2007) Axial disease in psoriatic arthritis. Curr Rheumatol Rep; 9:455 -60. 
Heuft -Dorenbosch L, Spoorenberg A, van Tubergen A, et al. (2003) Assessm ent of enthesitis 
in ankylosing spondylitis. Ann Rheum Dis; 62:127-32. In E, Turgut T, Gulkesen A, Yolbas S, Akgol G, Koca SS (2016) Sleep quality is related to 
disease activity in patients with ankylosing spondylitis. J Clin Rheumatol; 22(5):248- 252 
Julious SA, Patterson SD (2004) Sample sizes for estimation in clinical research. Pharmaceutical Statistics; 3:213 -215. 
[COMPANY_001] Confidential  Page 75  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
Langley RG, Elewski BE, Lebwohl M, et al (2014) Secukinumab in plaque psoriasis–results 
of two phase 3 trials. N Engl J Med; 371(4):326–38.  
Lukas C, Landewé R, Sieper J (2009) Development of an ASAS- endorsed disease activity 
score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis; 68(1):18-24. 
Machado PM, Landewé RB, van der Heijde DM (2011) Endorsement of definitions of disease 
activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheum; 38(7):1502-06. 
Manuel O, Kumar D (2008) QuantiFERON- TB Gold assay for the diagnosis of latent 
tuberculosis infection. Expert Rev D iagn; 8(3):247 -56. 
 
Marzo -Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin, R, Readie A, Richards HB, 
Porter B (2017) Secukinumab and sustained improvement in signs and symptoms of patients 
with active ankylosing spondylitis through two years: results from a phase III study. Arth Care & Res; 69(7):1020-1029. 
Mease PJ, McInnes IB, Kirkham B, et al (2015) Secukinumab inhibition of interleukin-17A in 
patients with psoriatic arthritis. N Engl J Med; 373(14):[ADDRESS_99442], Rahman P, van der Heijde D, 
Landewe R, Conaghan PG, Gottlieb A, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu (2015) Lancet; 386:1137-1146. 
Nemoto, O., M. Furue, H. Nakagawa, M. Shiramoto, R. Hanada, S. Matsuki, S. Imayama et 
al. (2016) The first trial of CIM331, a humanized antihuman interleukin -31 receptor A 
antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, 
tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. British Journal of Dermatology; 174: 296-304. 
Redfield, Margaret M., Kevin J. Anstrom, James A. Levine, Gabe A. Koepp, Barry A. 
Borlaug, Horng H. Chen, Martin M. LeWinter et al. (2015) Isosorbide mononitrate in heart 
failure with preserved eject ion fraction. New England Journal of Medicine; 373:2314-2324. 
Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54: 569–78. 
Sieper J, Rudwaleit M, Baraliakos X, et al (2009) The Assessment of SpondyloArthritis 
international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis.; [ADDRESS_99443] 2:ii1-44. 
Stokes ME, Davis C S, Koch GG (2012) Categorical data analysis using the SAS system. 3rd 
ed; Cary, NC: SAS Institute, Inc.  
Trudeau J, Van Inwegen R, Eaton T, Bhat G, Paillard F,  Ng D, Tan K, Katz NP (2015) 
Assessment of Pain and Activity Using an Electronic Pain Diary and A ctigraphy Device in a 
Randomized, Placebo -Controlled Crossover Trial of Celecoxib in Osteoarthritis of the Knee. 
Pain Practice; 15:247 -255. 

[COMPANY_001] Confidential  Page 76  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
van der Heijde D, Landewe RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, Ligozio G, 
Richards HB, Mpofu S (2016) Arth & Rheumatol; 68(8):1914-1921 
Yellen SY et al. (1997) Measuring Fatigue and Other Anemia-Related Symptoms with the 
Functional Assessment of Cancer Therapy (FACT) Measurement System. Journal of Pain and Symptom Management; 13:63-74. 
[COMPANY_001] Confidential  Page 77  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
13 Appendices  

[COMPANY_001] Confidential  Page 78  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  

[COMPANY_001] Confidential  Page 79  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
13.3 Appendix 3: Assessment of SpondyloArthritis International 
Society  criteria (ASAS) 
The ASAS response measures consist of the following assessment domains (Sieper 2009).  
ASAS domains: 
1. Patient’s global assessment of disease activity measured on a  NRS  
2. Patient’s assessment of back pain, represented by [CONTACT_90221], 
both measured on a NRS  
3. Function represented by [CONTACT_90203] [ADDRESS_99444] 2 questions on the 6- question BASDAI as 
measured by a NRS  
  
 
   
 
13.3.2  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
The BASDAI consists of a 0 through 10 scale ([ADDRESS_99445] problem, captured using a NRS ), which is used to answer 6 questions pertaining to the 5 major 
symptoms of AS: 
1. How would you describe your overall level of fatig ue/tiredness? 
2. How would you describe your overall level of neck, back or hip pain resulting from AS ? 
3. How would you describe your overall level of pain/swelling in joints other than the neck, 
back or hips? 
4. How would you describe your overall level of discomfort from any areas tender to the 
touch or pressure? 
5. How would you describe your overall level of morning stiffness from the time you wake 
up? 
6. How long does your morning stiffness last from the time you wake up? 
To give each symptom equal weighting, the mean (average) of the two scores relating to 
morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1 -4. The resulting 0 to 50 score is divided by 5 to give a final 0 – 10. 
BASDAI score. Scores of [ADDRESS_99446] suboptimal control of disease, and subjects with 
scores of 4 or greater are usually good candidates for either a change in their medical therapy or for enrollment in clinical studies evaluating new drug therapi[INVESTIGATOR_90165]. BASDAI is a quick and simple index (taking between 30 seconds and 2 minutes to complete).  

[COMPANY_001] Confidential  Page 80  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
13.3.3 Appendix 4: Guidelines for administering the PRO questionnaires 
 
1. Study coordinators should familiarize themselves with the PRO qu estionnaire(s) in the 
trial and identify any items where a patient’s response might highlight issues of potential 
concern. For example, one question in the SF-12 ‘How much of the time in the past [ADDRESS_99447] you felt downhearted and blue?’ If a patient responds ‘most or all of the time’, then the study coordinator should inform the study investigator.  
2. Patients should have adequate space and time to complete their questionnaires.  
3. Questionnaires should be administered and completed before the clinical exami nation. 
4. The administrator may clarify the questions but should not influence the response. 
5. Patients should choose one response for each question.  
Addressing Problems and Concerns  
Occasionally a patient may have concerns or questions about the questionnair es administered. 
Guidance related to some of the most common concerns and questions are given below. 
The patient does not want to complete the questionnaire(s)  
Tell the patient that completion of the questionnaire(s) is an important part of their participa tion 
in the study.  Patients that refuse to complete PRO questionnaires at Baseline, Week [ADDRESS_99448] be discontinued from the study per Section 5.6.2.  The goal of these questionnaires is 
to better understand the physical, mental, and social health problems of patients. Emphasize 
that this information is as important as any of the other medical information, and that the questionnaire(s) is simple to complete. Suggest that the questionnaire(s) may be diffe rent from 
anything the respondent has filled in the past.  
The patient is too ill or weak to complete the questionnaire(s)  
In these instances, the coordinator may obtain patient responses by [CONTACT_90222], followed by [CONTACT_90223], and entering the patient’s 
response. No help should be provided to the patient by [CONTACT_90224]. The coordinator should not influence patient responses. The study coordinator cannot translate the question into simpler language and has to be read verbatim. 
The patient wants someone else to complete the questionnaire(s)  
In no case should the coordinator or anyone other than the patient provide responses to the 
questions. Unless specified in the study protocol proxy data are not  an acceptable substitute for 
patient self -reported. Patients should be discouraged from asking a family member or friend for 
help in completing a questionnaire. 
The patient does not want to finish completing the questionnaire(s)  
If non -completion is a result of the patient having trouble understanding particular items, ask 
the patient to explain the difficulty. Re -read the question for them verbatim , but do not rephrase 
the question. If the respondent is still unable to complete t he questionnaire, that questionnaire 
will be forfeited since partial response will not be saved. Patients that refuse to complete PRO 
[COMPANY_001] Confidential  Page 81  
Amended Protocol Version 04 (Track Changes)   Protocol No. CAIN457FUS06  
 
 
questionnaires at Baseline, Week [ADDRESS_99449] be discontinued from the study per 
Section 5.6.2. 
The patient is concerned that someone will look at his/her responses  
Emphasize that all responses are to be kept confidential. Point out that their names do not appear 
anywhere on the questionnaire, so that their results will be linked with an ID number and not their name. Tell the patient that his/her answers will be pooled with other patients’ answers and that they will be analyzed as a group rather than as individuals. Tell the patient that completed questionnaires are not routinely shared with treating staff, and that their responses will only be seen by [CONTACT_90225]. Any response which may directly impact on or reflect their medical condition (e.g. noting of severe depression) will be communicated by [CONTACT_90226]. 
General Information about all questionnaire(s):  
All questionnaires are to be completed by [CONTACT_13935]. The questionnaires should be completed 
by [CONTACT_90227] a quiet area free from disturbance, and before any visit assessmen ts. Patients 
should receive no help from family members; if questions cannot be answered alone (due to problems with reading or understanding), then the doctor or nurse should read the questions verbatim without influencing their answers. The information provided is strictly confidential and will be treated as such.  
As there are no source data for the questionnaires, the data queries will be restricted to 
patient/visit information.  